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ABSTRACT

The ribosome is the quintessential antibacterial drug target, with many structurally and
mechanistically distinct classes of antibacterial agents acting by inhibiting ribosome function.
Detecting and quantifying ribosome inhibition by small molecules and investigating their
binding modes and mechanisms of action are critical to antibacterial drug discovery and
development efforts. To develop a ribosome inhibition assay that is operationally simple, yet
provides direct information on the drug target and the mechanism of action, we have developed
engineered E. coli strains harboring an orthogonal ribosome controlled green fluorescent protein
reporter that produce fluorescent signal when the O-ribosome is inhibited. As a proof of concept,
we demonstrate that these strains act as sensitive and quantitative detectors of ribosome
inhibition by a set of 12 structurally diverse 2-deoxystreptamine (2-DOS) aminoglycoside
antibiotics, which target the A-site in helix 44 of the 16S rRNA. To prove the generality and
promote the application of the system, we extended this system for detecting ribosome inhibition
by a variety of structurally and mechanistically distinct drug classes targeting both small and
V

large subunits of the ribosome. We have engineered E. coli strains capable of detecting Oribosome inhibition by other drugs targeting the 16S rRNA including the non-2-DOS
aminoglycosides streptomycin and kasugamycin, and the aminocyclitol spectinomycin. Through
integration of the Ribo-T tethered ribosome system with our system, we can also detect ribosome
inhibition by the 23S rRNA inhibitors erythromycin, lincomycin and linezolid. These results
suggest the generalizability of our strategy. We then applied the system to screen a set of
spectinomycin analogs with unknown activity to demonstrate potential application. Three
spectinomycin analogs were shown to possess higher or similar anti-ribosome activity compared
to the parent compound.
We have also modified our system to enable rapid directed evolution of rRNA variants
with specific properties from large rRNA libraries to study the impact of rRNA sequence
variation on ribosome activity and drug resistance. By replacing the fluorescence reporter gene
with the chloramphenicol acetyltransferase (CAT) gene, we are able to select for functional
rRNA mutants and quantify their catalytic activities. A variety of drug-resistant and drugdependent rRNA mutants, as well as hyper- and hypo-active mutants were found. We also
performed directed evolution to select ribosome mutants capable of supporting cell growth, yet
confer resistance to aminoglycoside antibiotics. Only two mutants (A1408G and G1491U) were
identified from this experiment; and both mutants have broad spectrum aminoglycoside
resistance. Our results demonstrate that the O-ribosome controlled reporter system is capable of
efficiently identifying new rRNA mutants with unique properties. We suggest that our directed
evolution approach has the potential to provide new insights into mechanisms of ribosome
inhibition and evolution of antibiotic resistance.
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CHAPTER 1. BACKGROUND AND SIGNIFICANCE
1. The bacterial ribosome is the major target for antimicrobial agents.
Antibiotics are one of the greatest medical innovations in human history. However,
antibiotic resistance has arisen with the development of antibiotics. The continuous emergence of
drug-resistant pathogens has greatly impacted human health.1 It has become a major social issue,
and even a popular cause of human extinction in disaster films. According to the World Health
Organization (WHO), around six percent of all death in the world is caused by bacterial infection;
and is the primary cause of death in low-income nations.

2

Unfortunately, due to economic

concerns, many large pharmaceutical companies have discontinued their antibiotic development
programs in recent years. Only 14 new antibiotics have been approved and sold in the past 15
years. 3 However, due to the fact that drug resistance will continue to emerge due to the evolution
of bacterial pathogens, research on development of antimicrobial agents and their mechanisms
must continue. There are reports of newly isolated drug resistant pathogens every year all over
the world. In 2011, the super-resistant Gonorrhea strain H041, which is resistant to all known
antibiotics, was found in Japan.

4

In 2015, the Listeria outbreak from Blue Bell ice cream

products caused serious concern and panic on the social media.

5

In 2016, the ‘nightmare

bacteria’, a multi-drug resistant E.coli, was identified in the US; and was found to be resistant to
the “antibiotic of last resort” colistin. 6 These are just a few examples found mainly in developed
countries. There are many unreported cases all over the world. Figure 1-1 shows the spread of
drug resistance against commonly used antibiotics worldwide. 7 As globalization continues, the
risk of ‘super-bugs’ spreading worldwide will increase if we fail to address this issue.

1

Figure 1-1. The spread of drug resistance to common antibiotics. 7
To develop novel antimicrobial agents, it is important to study both the mechanisms of
action of drugs and the mechanisms of resistance to these drugs. Antibiotics kill bacterial
pathogens by targeting essential cellular components. Currently there are several well
characterized antibiotic targets in bacteria (Figure 1-2). For instance, β-lactams and their
derivatives target cell-wall synthesis, trimethoprim targets folic acid metabolism, quinolones
target DNA gyrase and rifamycin targets RNA polymerase. 8 Among all antibiotic targets, the
ribosome is the most common. More than 50% of natural and synthetic antimicrobial agents
inhibit bacterial pathogens by targeting the ribosome9 (Figure 1-3). The ribosome is a complex
bimolecular machine found in all living cells. The ribosome is the protein synthesis machinery
that catalyzes the formation of the polypeptide chain. It is an essential cellular component to
support cell survival and growth. In most bacteria, the ribosome is the most abundant
2

intracellular structure. Although the structure and function of the ribosome are phylogenetically
conserved across all bacterial species, there are significant structural differences between
prokaryotic and eukaryotic ribosomes. 10 The eukaryotic ribosome is larger than the prokaryotic
ribosome. This is reflected by the sedimentation coefficient (80S vs. 70S) and the molecular mass
(3.2×106 vs 2.0×106). The length of rRNA sequence is also different between eukaryotic
ribosome and prokaryotic ribosome. 11 These differences make it possible to develop inhibitors
that selectively target the bacterial ribosome. Therefore, the essentiality of the ribosome and the
differences between prokaryotic and eukaryotic ribosomes make the ribosome an excellent target
for antimicrobial agents. 12 The fact that the ribosome is the most frequent target of antibacterial
agents is likely due to the abundance of the ribosome in the cell, its essentiality, and its ancient
origin.

Figure 1-2. Targets of antibiotics8

3

Figure 1-3. Cheminformatic analysis of natural product chemotypes and their target sites9
The structure and function of bacterial ribosome and protein synthesis have been well
studied, aided greatly by X-ray crystallography. The bacterial ribosome consists of three
ribosomal RNA (known as 23S, 16S and 5S rRNA) and 54 ribosomal proteins. The ribosomal
RNA is a ribozyme which catalyzes peptide bond formation at the peptidyl-transferase center
(PTC). 13 Functional studies of ribosomal proteins are ongoing. In general, the proposed function
of the ribosomal proteins is to coordinate ribosome subunit assembly. 14 The protein synthesis
process includes 4 major steps: translation initiation, elongation, termination and ribosome
recycling. Translation initiation is the rate limiting step in the protein synthesis. It involves the
formation of 30S initiation complex, 50S recruitment and 70S assembly. 15 Translation elongation

4

involves the delivery of aminoacylated tRNA to the decoding site (A-site), peptide bond
formation, tRNA translocation and nascent peptide elongation inside the exit tunnel. Elongation
is terminated by binding of release factors. As a result, the polypeptide is released from the
ribosome and the ribosome will be recycled for the next round of translation. 16 Most components
of the ribosome, and all steps of translation, are essential for protein production by the cell.
Therefore protein synthesis is quite fragile; and any molecule that can interfere with translation
can adversely affect cell survival.
There are many classes of antimicrobial agents that target the bacterial ribosome. A few
of these are clinically used antibiotics, while others are used in the laboratory for ribosome
functional studies. In general, they can be divided into 2 groups: those that inhibit the small
ribosomal subunit and those that inhibit the large ribosomal subunit inhibitors. Nearly all small
subunit inhibitors are small molecules. Their mechanisms of action have been studied in detail
by using biochemical techniques17,

18, 19

, X-ray crystallography16,

20, 21

and single molecule

techniques. 22, 23 As a result of advances in X-ray crystallography of the ribosome, representatives
of most major classes of ribosome inhibitors have been co-crystallized with the 70S ribosome. 16
Different types of small subunit inhibitors target different sites on the ribosomal small subunit;
but in general they are clustered along the path that the mRNA and tRNAs follow during
translation (Figure 1-4). The mechanisms of action of different classes of molecules are distinct.
For instance, aminoglycoside antibiotics bind to the h44 region (decoding site), which blocks
translocation of mRNA-tRNA and induces miscoding during translation. Tetracycline class
antibiotics bind to the h31 region (near the P-site) and block incoming tRNA from binding.
Kasugamycin binds to the h24 (also near the P-site) and prevents the recognition of the start
codon by the initiator tRNA. 16
5

Figure 1-4. Antibiotics targeting the small ribosomal subunit21
Large ribosomal subunit inhibitors are comprised of both small molecules and peptides of
intermediate molecular weight.

21

Unlike small ribosomal subunit inhibitors, which bind to

several distinct sites, most large subunit inhibitors bind in or near the peptidyl-transferase center
(PTC) (Figure 1-5). This is probably due to the importance of the PTC as the catalytic center of
ribosome responsible for catalyzing peptide bond formation. However, there are also two known
classes of antibiotics that target other regions of the 23S rRNA. Orthosomycins bind to H89 and
H91, and block the binding of initiation factor 2 (IF2) to the translation initiation complex. 24
Thiopeptides bind to H43 and H44, and block the binding of elongation factors (EF-G and EFTu). 25 Large subunit inhibitors that target the PTC can be divided into two groups based on their
mechanisms of action. Group 1 is comprised of the antibiotics that bind to the PTC itself, such as
chloramphenicol, lincosamides, oxazolidinones, puromycin, sparsomycin, blasticidin S, pleuromutilin and streptogramin A. Among these antibiotics, some bind to the A-site and compete with
the incoming tRNAs (chloramphenicol, lincosamides, oxazolidinones, puromycin and
6

sparsomycin). Others bind to both A-site and P-site of the PTC (blasticidin S, pleuromutilin and
streptogramin A)16, preventing correct positioning of the aminoacylated ends of tRNAs. Group 2
is comprised of the antibiotics that bind to the nascent polypeptide exit tunnel (NPET). They
include the macrolides and streptogramin B. By binding to the NPET, they block elongation of
the nascent peptide and cause premature peptidyl-tRNA release, which terminates translation. 16
In addition to these two groups of large subunit inhibitors, it has been recently shown that the
proline-rich antimicrobial peptides (PrAMPs) also target the ribosome by binding to the NPET.
The PrAMPs were previously thought to target heat-shock protein DnaK. However, recent
studies show that PrAMPs bind to DnaK with very low affinity. Ribosome/PrAMP co-crystal
structures and biochemical evidence indicate that the ribosome is likely the true target site of
PrAMPs. 26 This finding could lead to new peptide-based antimicrobial agents. Figure 1-6 is an
overview of the known target sites and modes of action of translation inhibitors.

Figure 1-5. Antibiotics targeting the large ribosomal subunit21

7

Figure 1-6. Overview of the known target sites and modes of action of translation inhibitors. 16
Ede represents edeine; Kas represents kasugamycin; Pct represents pactamycin; Tnb represents
thermorubin; Avn represents avilamycin; Evn represents evernimicin; Ths represents
thiostrepton; Stp represents streptomycin; Tet represents tetracyclines; Tig represents tigecycline;
Bls represents blasticidin S; Cam represents chloramphenicol; Cln represents clindamycin; Lnz
represents linezolid; Plu represents pleuromutilins; Pmn represents puromycin; S A represents
streptogramin A; Spr represents sparsomycin; HygB represents hygromycin; Neo represents
neomycin; Par represents paromomycin; Fus represents fusidic acid;
Spt represents
spectinomycin; Ery represents erythromycin; Tel represents telithromycin.
Although ribosome is the most frequent target for antimicrobial agents, the number of
target sites on ribosome is relatively small considering the large size of ribosome. A potential
avenue for developing new antimicrobial agents is to identify new target sites on the bacterial
ribosome. Yassin et al searched for the deleterious mutations on rRNA by functional screening
of randomly mutated 16S and 23S rRNA libraries. 27 They proposed that sites where deleterious
mutations were found are potential new antibiotic target sites due to their essentiality for
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ribosome function. Cunningham et al also examined deleterious mutations on rRNA to identify
potential new antibiotic target sites. 28 Instead of generating an rRNA library on the E. coli wild
type 16S rRNA (as Yassin et al had done), they generated a randomly mutated rRNA library on
an orthogonal 16S rRNA gene that controls the expression of a reporter gene. Since engineering
the orthogonal ribosome doesn’t interfere with the cell growth and deleterious mutations can also
be studied, they proposed that this system could be used to comprehensively study ribosome
sequence/function relationships. Both methods aim to identify functionally important sites in 16S
rRNA. Although these methods have potential for identifying new druggable sites on the
ribosome, they have not yet led to the discovery of new drugs or drug leads.
2. Technology for detecting and studying ribosome inhibition.
Methods to determine drug potency and study drug mechanisms of action are critical for
discovery and development of new antimicrobial agents. Due to the importance of the ribosome
as a drug target, several methods have been developed to determine the potency and study the
mechanism of action of ribosome inhibitors. In general, these methods can be divided into in
vitro methods and in vivo methods. Currently, in vitro methods are more amenable to performing
high-throughput screening. However, in vivo methods can provide information that is more
directly relevant to treating bacterial infections because they use live cells. Both in vitro and in
vivo methods can provide useful information to assist in the development of new antimicrobial
agents.
In vitro methods to detect and study ribosome inhibition are usually used to identify the
target site and to validate the mechanism of action after identification of initial hit compounds
from phenotypic screening. Several in vitro methods and systems for assaying ribosome
inhibition have been developed. The most well-known method is the in vitro translation assay.
9

Due to its simplicity and accuracy, it is widely used in both academic labs and the
pharmaceutical industry. . In vitro translation assays are typically performed as coupled
transcription-translation assays using a DNA template encoding a reporter protein and E. coli S30 extracts. Luciferase is the most commonly used reporter for in vitro translation assays. Using
the substrate luciferin, which is converted by luciferase to a chemiluminescent product, the
relative amount of translation that occurred in a reaction over the time period of the assay can be
determined without carrying out protein purification (Figure 1-7). 29 Fluorescent or radioactive
proteins can be also used as reporters, but require protein purification prior to assay readout. In
an in vitro translation assay, inhibition of translation can be detected and quantified by observing
the decrease in production of reporter protein compared to a positive control. In vitro translation
reactions can be miniaturized, and thus are amenable to high-throughput assay platforms. Lowell
at al used in vitro translation assay to screen a collection of natural product extracts and identify
several new ribosome inhibitors. 30 In vitro translation assays employing extracts from cells
expressing mutant rRNA have been used to address the issue of drug selectivity toward
prokaryotic ribosomes. The Böttger group has engineered the h44 region of 16S rRNA in
Mycobacterium smegmatis to create hybrid ribosomes which contain a eukaryotic h44 region.
Surprisingly, the resulting hybrid ribosomes can support cell survival and growth in the absence
of a wild type copy of 16S rRNA. 31 By isolating these hybrid ribosomes from the engineered M.
smegmatis strain and using them in an in vitro translation assay with a luciferase reporter,
aminoglycoside antibiotic analogs that are incapable of binding to the eukaryotic h44 site were
identified. This system has proven to be an effective way of reducing the side effects of some
aminoglycoside antibiotics toward human cells.

10

Figure 1-7 In vitro translation assay for detecting and quantifying ribosome inhibition29
X-ray crystallography is another well-known and widely used in vitro technique to study
ribosome inhibition through structural determination of ribosome-drug complexes. Because the
ribosome is a large and complex biomolecule, it was extremely challenging to solve its structure.
The first high resolution ribosome X-ray crystal structures were not solved until late 1990s. First,
the Steitz group and the Yonath group solved structures of the large ribosomal subunits from
Haloarcula marismortui32 and Deinococcus radiourans33, respectively. Shortly after, the
Ramakrishnan group solved the structure of the small ribosomal subunit from Thermus
thermophilus. 34 These achievements led to receipt of the Nobel Prize in chemistry by these three
groups in 2009. With continued advances in X-ray crystallography, additional ribosome
structures, including those of the E. coli and T. thermophilus 70S ribosomes in complex with a
number of ribosome inhibitors have been solved to date. As an example, Figure 1-9 shows the
structure of spectinomycin bound to the E. coli 70S ribosome. The ability to solve ribosome-drug
co-crystal structures has enabled structure-based drug design of ribosome inhibitors. This
approach has been proved invaluable in the development of new antimicrobial agents. For
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instance, Rib-X Pharmaceuticals used a structure-based approach to design a series of new
oxazolidinone compounds with enhanced activity against drug-resistant pathogens. 35 The Lee
group also used computer-aided design of new spectinomycin analogs based on the ribosomespectinomycin co-crystal structure. 36 They rationally engineered the 3’ ketone group in the Cring of spectinomycin and generate a series of new compounds. Phenotypic assays demonstrated
that some of these new compounds possess improved bioactivity against certain drug resistant
pathogens. In summary, the availability of ribosome-drug co-crystal structures has accelerated
the development of improved ribosome inhibitors.

Figure 1-9 Crystal structure showing interactions between spectinomycin and the ribosome
Although X-ray crystallography is a powerful tool to study ribosome-drug interactions, it
does not provide information on the effects of inhibitors on the kinetics and dynamics of the
ribosome during translation. In recent years single molecule techniques have been used to study
changes in ribosome dynamics resulting from inhibition by small molecules. The Puglisi lab used
single-molecule fluorescence measurements combined with structural and biochemical
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techniques to study the effects of apramycin, paromomycin and gentamicin on ribosome function.
22

Although these three drugs bind to the same pocket of the ribosome, and all three were shown

to cause miscoding during translation elongation, ribosome dynamics differed in the presence of
each of the three drugs. Paromomycin and gentamicin displace the nucleotides A1492 and
A1493 and block the intersubunit rotation. Apramycin has only little effect on A1492 and A1493
and causes limited miscoding. The Blanchard lab used single-molecule FRET (fluorescence
resonance energy transfer) to study aminoglycoside-ribosome interactions. 23 They found that
neomycin and paromomycin, which only differ in the identity of the ring-I 6′-substitutent, drive
ribosome subunit rotation in different directions. Single-molecule techniques allow us to observe,
in unprecedented detail, the effects of antibiotics on the ribosome; and are exciting new tools for
studying ribosome inhibition.
RNA footprinting is one of the oldest in vitro methods to identify binding sites of
ribosome inhibitors. The Noller lab used RNA footprinting to identify the binding sites of several
small ribosomal subunit inhibitors (streptomycin, tetracycline, spectinomycin, edeine,
hygromycin and neomycin) in 1987. 37 A variation on this technology, toe-printing, has been
used to identify sites on mRNA where ribosomes treated with drugs stall. Toe-printing uses the
drug bound ribosome-mRNA complex derived from cell-free translation reactions as a template
for reverse transcriptase PCR (RT-PCR). The RT-PCR reaction will terminate near the site
where the ribosome has stalled. By running a DNA sequencing gel, the drug bound ribosome
stalling site can be identified. This method is useful for studying the mechanisms of action of
certain ribosome inhibitors, particularly those that act by blocking the polypeptide exit tunnel.
The Mankin lab used toe-printing analysis to study erythromycin-dependent ribosome stalling. In
this study, they determined that the sequence of amino acids of the nascent polypeptide, which
13

interact with bound drugs in the polypeptide exit tunnel, is the key factor that differentiates the
mechanisms of action of erythromycin and telithromycin. 38 They also used toe-printing analysis
to determine that different ribosome inhibitors display distinct ribosome stalling patterns.39 These
patterns can be used to differentiate ribosome inhibitors.
The Deuerling lab recently developed an assay system to identify conditions under which
ribosome assembly is impaired. In this system, both the small and large subunit ribosomal
subunits are fluorescently labeled.

40

By measuring the relative fluorescence intensity under

various conditions, ribosome assembly can be studied, and the relative assembly rate can be
calculated. Using this system, they demonstrated that the fluorescence intensity changes
dramatically in the absence of ribosome assembly factors. They also found that the ribosome
inhibitors erythromycin and chloramphenicol do not lead to obvious changes in fluorescence
intensity, indicating that these two ribosome inhibitors do not affect ribosome assembly. This
assay system offers a potential new way to identify inhibitors that specifically target ribosome
assembly, and provides a new toolto study the mechanisms of action of known ribosome
inhibitors on a deeper level.
As a final example of an in vitro method for studying ribosome inhibition, the Mankin lab
developed a method whereby an environmentally sensitive fluorophore was installed at several
sites of ribosomal protein S12. The fluorescence intensity of the fluorophore will change if an
inhibitor binds at a nearby site. Using this method, they were able to determine the K d values of
several ribosome inhibitors. These Kd values correlated well with those obtained using
previously published methods. In theory, this approach is general provided that an
environmentally sensitive fluorophore can be installed at the desired site.
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In contrast to in vitro methods, in vivo methods for studying ribosome inhibition are
limited due to the fact that ribosome is an essential cellular component. There are several reports
describing the development of biosensor strains to detect ribosome and translation inhibition.
The Karp lab developed an engineered E.coli strain which uses a luciferase reporter gene
controlled by a temperature sensitive promoter, bacteriophage λ leftward promoter. 42 Ribosome
inhibition was detected and quantified by measuring the luminescence signal upon promoter
induction in the presence and absence of inhibitor. This method was able to detect the ribosome
inhibition by a panel of known inhibitors. This assay is performed over a 30-45 minute time
period due to negative effects on cell viability after exposure to the drug. Later, the authors also
improved the signal intensity of the biosensor system by replacing the bacteriophage λ promoter
with the tetracycline inducible promoter. 43 The assay can also be performed using lyophilized
cells. However, low signal intensity and propensity for error limit application of the system.
Another biosensor system to detect ribosome inhibition was developed by Sergiev Lab. 44
They used an engineered tryptophan attenuator trpL placed upstream of a cerulean fluorescent
reporter gene. Replacement of two tryptophan codons in trpL with alaninerenders trpL
translation independent of the concentration of tryptophan. In the absence of ribosome inhibitors,
the trpL mRNA adopts a secondary structure that prevents translation of the reporter gene. In the
presence of sub-lethal concentration of ribosome inhibitors, the drug-bound ribosome will stall at
the trpL sequence with increasing frequency, which relieves repression of the reporter gene and
results in a fluorescent signal. The biosensor can detect a variety of both small and large
ribosomal subunit inhibitors with sub-lethal concentration; and has been used to identify the new
ribosome inhibitor amicoumacin A.

45

The disadvantage of this system is that it is not

quantitative, and therefore can only be used to detect ribosome inhibitors.
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Use of a similar attenuator-based system to detect ribosome inhibition by macrolides and
ketolides was recently reported.46 The Mankin lab used the leader sequence of the ermC gene
(ermCL) to control the expression of the LacZ reporter gene. 46 ermCL is a regulatory sequence
naturally found upstream of the ermC rRNA methyltransferase resistance gene in the
erythromycin biosynthetic gene cluster.

In the absence of 14-membered ring macrolides or

ketolides, ermCL forms a secondary structure that can prevents expression of downstream genes.
In the presence of these compounds, the drug-bound ribosome will stall in the ermCL region,
changing the secondary structure and allowing translation of downstream genes. This system can
be used to detect 14-membered ring macrolides and ketolides, but not 16-membered ring
macrolides or other ribosome inhibitors.
A number of biosensors capable of detecting specific natural products, including some
ribosome inhibitors, not via their interaction with the ribosome, but through interaction with a
transcriptional regulator, have been developed. For example, the Karp lab developed a
tetracycline biosensor which uses a tetracycline responsive transcriptional repressor protein
together with its promoter/operator sequence controlling a gene encoding a bioluminescent
reporter. 47 In the presence of tetracycline class compounds, the repressor protein will dissociate
from the promoter upon drug binding, allowing transcription of the promoter gene.
In addition to the in vivo systems described above, measuring the growth inhibitory
effects of ribosome inhibitors on bacterial pathogens can also be considered an in vivo method to
evaluate the ribosome inhibition if the compound being studied is already known to be a
ribosome inhibitor. This method is usually referred as the minimum inhibitory concentration
(MIC) assay. By measuring concentration dependent growth inhibition of a wild type bacterial
strain or one carrying a ribosomal resistance mutation, the potency of the compound against a
16

specific bacterial strain can be evaluated. Limitations of this method are that it requires the
appropriate laboratory environment for working with pathogenic bacterial strains, and it does not
provide any a priori information regarding the target of the compound.
In summary, both in vitro and in vivo technologies for detecting and studying ribosome
inhibition are useful and valuable for drug development efforts. In vitro methods and systems are
more favorable because they are fairly straightforward to develop, and produce results that are
often more accurate than in vivo techniques. However, in vitro techniques are more difficult to
carry out from a technical standpoint. For example, in vitro translation systems employ reagents
that require specialized skill to prepare, and are expensive to purchase. Others, such as X-ray
crystallography and single-molecule techniques, require specialized instruments and skills to
perform the experiments and analyze the data. In vivo techniques, on the other hand, are
generally more amenable to being carried out in a typical laboratory setting. The disadvantages
of most in vivo techniques are that they are not quantitative, and do not provide direct
information on the interactions between drugs and their targets. Other disadvantages of in vivo
systems are that most in can only detect the ribosome inhibitors at sub-lethal concentrations, and
thus cannot accurately assess compound potency; and are narrow with respect to the compounds
they can detect. While the currently availablein vitro and in vivo techniques have greatly
facilitated the identification and mechanistic study of ribosome inhibitors, there is a need for
additional tools that allow simple, high throughput, inexpensive study of ribosome-drug
interactions in living bacterial cells.
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3. Summary and thesis statement.
Due to the fact that drug-resistant pathogens continually evolve resistance mechanisms
upon exposure to new drugs, discovery and development of antimicrobial agents is critical to
human health. Current efforts to advance antimicrobial drug discovery include natural product
biosynthetic engineering, structure-based drug design, bioinformatics-guided discovery of novel
natural products, and exploring novel therapeutic approaches that are less susceptible to drug
resistance. 48 Technologies that can evaluate the activity and study the mechanism of action of
compounds generated from these drug development efforts are important for efficiently
identifying new drugs and drug leads. Since the bacterial ribosome is the most frequent target for
antimicrobial agents, technologies that can detect and study ribosome inhibition by small
molecules will greatly accelerate the drug development process.
The work described in this dissertation focuses on the development of novel in vivo
systems for simply and accurately detecting, quantifying, and studying ribosome inhibition.
These systems are based on novel orthogonal ribosome-controlled reporter systems. Chapter 2
describes the development of in vivo systems for detecting and quantifying ribosome inhibition
by aminoglycoside antibiotics. This system was constructed using an orthogonal ribosomecontrolled fluorescent reporter, and was used to examine the potency of a panel of 12
aminoglycoside antibiotics in parallel. The drug activity data obtained using these systems
correlate well with previous results obtained using an in vitro translation assay.
As described in Chapter 3, these systems were then extended to detect and quantify
ribosome inhibition by other small ribosomal subunit inhibitors with binding sites distinct from
that of aminoglycosides, including spectinomycin, kasugamycin, and streptomycin. As a proof of
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concept, a spectinomycin detection strain was used to screen a set of chemically synthesized
spectinomycin analogs which were designed based on the spectinomycin-ribosome co-crystal
structure. Three compounds were identified as having ribosome inhibitory activity activity
comparable to or higher than the parent compound. To extend the system to detect inhibitors that
bind to the large ribosomal subunit, we employed engineered tethered ribosomes (RiboT) in
conjunction with our detection system. The resulting systems are capable of detecting the large
ribosomal subunit inhibitors erythromycin, lincomycin, and linezolid. Although some detection
systems required optimization during the development process, each final optimized system is
ready to use for drug screening applications, and is amenable to high-throughput assay platforms.
Potential future applications of these systems include detecting ribosome inhibitors from natural
product extracts, engineering natural product biosynthetic enzymes and pathways in vivo, and
screening compound libraries for ribosome inhibitors.
Identifying drug resistance mutations is an important step both in understanding the
mechanism of action of a drug and in assessing the ease with which resistance to the drug can
arise due to mutation. Use of orthogonal ribosome systems creates a population of ribosomes
free from the constraints of essentiality, which facilitates studies of the effects of rRNA
mutations on drug resistance and ribosome fitness. As described in Chapter 4, we used an
orthogonal ribosome-controlled selectable marker together with a directed evolution approach to
identify mutant rRNA sequences that confer aminoglycoside resistance or dependence; or that
affect ribosome fitness, from a large A-site saturation mutagenesis library. We identified and
characterized a pool of novel rRNA mutants obtained from selections without aminoglycoside
and in the presence of each of the three aminoglycosides kanamycin, neomycin, and gentimicin.
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We identified novel aminoglycoside resistant and aminoglycoside dependent mutants, and both
hyper- and hypo-active mutants using this approach.
In summary, the work described in this dissertation provides a set of new and powerful
tools for detecting, quantifying and studying ribosome inhibition. The engineered E.coli strains
developed in this work are non-pathogenic and simple to culture. The fluorescence quantification
method is general and easy to perform. Therefore, we anticipate that these tools will find broad
utility both in the medicinal chemistry and ribosome molecular and synthetic biology
communities.
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CHAPTER 2. DEVELOPMENT OF DETECTION AND
QUANTIFICATION SYSTEMS FOR RIBOSOME INHIBITION BY
AMINOGLYCOSIDE ANTIBIOTICS
1. Introduction
The ribosome is a complex, highly conserved biomolecular machine essential for the
biosynthesis of cellular proteins and peptides. The essentiality and ancient origin of the ribosome
have made it one of the most frequent targets of antibacterial natural products. 1 Of the many
known classes of ribosome inhibitors, the aminoglycosides (Figure 2-1) are perhaps the beststudied with regard to their mechanisms of action,2 − 4 drug resistance,2 − 4 and biosynthesis.5 − 7
Aminoglycosides are a clinically useful class of ribosome inhibitors with broad spectrum activity
toward a variety of microbial pathogens. However, their widespread clinical use has been
hampered by low-level toxicity to human mitochondrial ribosomes.2 − 4 Aminoglycosides can
impair ribosome function by affecting the efficiency of intersubunit rotation,8

− 10

translocation,2,3,11,12 and ribosome recycling8 and by inducing translational miscoding2 − 4,13
through specific interactions with the decoding site (A-site) of the 16S rRNA in helix 44 (h44) of
the small (30S) ribosomal subunit14−17 (Figure 2-1), and in the case of some aminoglycosides,
with helix 69 (H69) of the large (50S) ribosomal subunit.8,10,12,15,18 Aminoglycosides also show
promise as treatments for other diseases, including HIV2, human genetic disorders, where their
ability to induce miscoding has been used to suppress disease-associated premature termination
codons,2,19 and fungal infection, where amphiphilic aminoglycoside analogs have been shown to
perturb the function of the fungal plasma membrane.20
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Figure 2-1 (A) Structures of aminoglycosides used in this study. (B) Overlayed X-ray crystal
structures of the decoding site (A-site) of the E. coli 16S rRNA with select aminoglycosides
bound. Residues 1403−1411 and 1489−1498 of 16S rRNA are shown in gray. Aminoglycosides
are color-coded as follows, and the source PDB file for each is given in parentheses: kanamycin
A, maroon (2ESI23); gentamicin, purple (2QB915); geneticin (G418), pink (1MWL22); neomycin
B, dark green (2QAL15); paromomycin, light green (2Z4K15); apramycin, orange (4AQY17);
hygromycin, blue (3DF116).
Much of our current understanding of aminoglycoside/rRNA interactions, potency as
ribosome inhibitors, and mechanisms of action comes from in vitro studies. The target sites of
several aminoglycosides were first identified using RNA footprinting14 and were later examined
in detail by X-ray crystallography.

15 −17,21,22

Affinities of aminoglycosides for rRNA hairpins

mimicking the A-site have been assessed using mass spectrometry,23 surface plasmon resonance
(SPR),24 NMR,18 and competition assays.25 However, it has been observed that binding affinities
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of some aminoglycosides to A-site rRNA mimics do not correlate linearly with inhibition of
translation in vitro or antibacterial potency in vivo,26 indicating that the results of assays using Asite mimics are not fully equivalent to those obtained when employing intact ribosomes in vitro
or in vivo. Ribosome inhibition is also commonly measured directly using in vitro translation
systems. These studies have revealed that individual aminoglycosides differ significantly with
respect to their potencies as ribosome inhibitors.26 − 30 Recently, such systems have been
combined with powerful single molecule techniques such as smFRET to probe the effects of
aminoglycosides on the kinetics and dynamics of the individual steps of translation, revealing
that individual aminoglycosides differ markedly with respect to their effects on these steps.8−10,12
However, in vitro translation experiments designed to investigate drug binding mode or
mechanism of action are technically challenging to carry out, and in vitro translation assays in
general either require expensive reagents or specialized preparation methods and cannot provide
information on in vivo properties such as compound membrane permeability or efflux.
In contrast to the breadth of techniques available for in vitro studies, in vivo analyses of
the effects of aminoglycosides have been limited to measuring the growth inhibitory effects
(most commonly reported as minimum inhibitory concentrations, MICs) of the compounds on
wild-type bacterial strains and on those carrying ribosomal resistance mutations.31−33 Although
such assays are operationally simple and provide direct information on a compound’s ability to
inhibit bacterial growth, they do not provide any information a priori regarding the biomolecular
target(s) of a drug (the ribosome in the case of aminoglycosides), the target binding site(s) (the
A-site, and in some cases H69 for aminoglycosides), or the mechanism(s) by which a drug exerts
its effects on the target.
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Considering the limitations of existing in vitro and in vivo technologies, we envisioned an
alternative in vivo strategy for investigating ribosome inhibition by small molecules that
combines the ability of in vitro assays to quantitatively probe the effects of binding to a specific
target site with the operational ease and in vivo relevance of live cell antibacterial assays. This
strategy utilizes orthogonal ribosomes (O-ribosomes) - specialized mutant ribosomes that, by
virtue of a mutated 16S rRNA anti-Shine-Dalgarno (ASD) sequence, are unable to translate
native mRNA, yet retain the ability to translate mRNA carrying a complementary mutant ShineDalgarno (SD) sequence34−36 to circumvent the limitations imposed by ribosome essentiality. We
hypothesized that O-ribosomes, if used to control expression of an engineered genetic circuit that
results in a quantifiable “turn-on” phenotype upon ribosome inhibition, could be used to quantify
ribosome inhibition by aminoglycosides or other ribosome inhibitors, providing a means of
rapidly assessing the target specificity and ribosome inhibiting potency of these compounds in
live bacterial cells. Such an O-ribosome-based assay would facilitate studies of mechanisms of
drug action and of the relationship between target rRNA sequence and drug activity that can lead
to discovery of ribosome inhibitors with improved therapeutic properties.
Our aminoglycoside responsive strains were designed to harbor an engineered plasmidborne reporter system comprised of three elements (Figure 2-2): (1) a constitutively expressed
aminoglycoside-sensitive orthogonal 16S rRNA (O-16S) gene bearing a mutated anti-ShineDalgarno (O-ASD) sequence,35 (2) the tetR gene encoding a constitutively expressed
tetracycline-responsive repressor protein TetR37 with orthogonal SD (O-SD) sequence
complementary to the 16S rRNA OASD sequence,35 and (3) the gfp-uv gene encoding green
fluorescent protein variant GFPuv38 under transcriptional control of the TetR-repressed promoter
PLtetO-1.39 In the absence of aminoglycoside (Figure 2-2), cells bearing these three elements
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would produce O-ribosome-derived TetR that represses transcription of gfp-uv, resulting in no
fluorescence. However, in the presence of aminoglycoside (Figure 2-2), the O-ribosome is
inhibited, resulting in a reduced level of TetR, derepression of gfp-uv transcription, and
production of GFP. The system is designed to be highly sensitive by substantially amplifying the
aminoglycoside input signal through transcription and translation of gfp-uv, resulting in
production of multiple GFP proteins per aminoglycoside molecule.

Figure 2-2. (A) Schematic showing the functionality of the orthogonal ribosome-controlled
fluorescent reporter in the absence (left panel) and presence (right panel) of aminoglycoside. The
O-16S rRNA is shown in black, O-SD/O-ASD pair is shown in red, tetR mRNA and TetR
protein are shown in cyan, PLtetO-1 is shown in blue, the gfp-uv gene and GFP protein are
shown in green, and aminoglycoside is shown as a red hexagon. (B) Cell pellet fluorescence and
fluorescence quantification of E. coli DH5α cells transformed with individual and combined
functional elements of the orthogonal ribosome-controlled fluorescent reporter.
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To protect the E. coli host itself from inhibition by aminoglycosides, the strain’s native
rRNA was made aminoglycoside resistant using a previously developed host, E. coli SQ380, in
which all seven chromosomal copies of the rRNA operon were deleted and replaced by a single
rRNA operon on plasmid prrnC-sacB bearing the counter-selectable marker sacB gene. The
A1408G 16S rRNA mutation, which confers resistance to many aminoglycosides,
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was

introduced into rRNA operon expressing plasmid pRRSH2. The resulting plasmid, pRRSH2A1408G, was used to replace prrnC-sacB in SQ380. The aminoglycosides resistant strain was
then used as the host to harbor the O-ribosome-controlled tetR-gfpuv genetic circuit.
Here, we have created engineered E. coli strains harboring the O-ribosome-controlled
green fluorescent protein (GFP) reporter that are non-fluorescent in the absence of a drug but
express GFP upon O-ribosome inhibition. We show that these strains are able to detect ribosome
inhibition by a collection of 12 structurally diverse aminoglycosides in a highly sensitive, dosedependent manner with essentially no background. The fluorescence dose response patterns we
observed for engineered E. coli detection strains treated with these aminoglycosides correlate
with the results of in vitro translation inhibition assays, validating the accuracy of our assay in
assessing the potencies of aminoglycosides as ribosome inhibitors. Our results provide a full
comparative assessment of the ribosome inhibiting potencies of the 12 aminoglycosides assayed.
Thus, the O-ribosome reporter system developed here provides a powerful new tool for easily
and rapidly assessing the relative potencies of aminoglycosides as ribosome inhibitors in live
bacterial cells.
2. Experimental procedures
General. All general molecular biological and biochemical reagents, including Luria
Bertani (LB) media (Miller), were purchased from VWR (Atlanta, GA) and were used without
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further purification. Water used for media was obtained from a Barnstead/Thermolyne HN
Ultrapure water purification system. Gentamicin sulfate, paromomycin sulfate, geneticin (G418)
sulfate, neomycin sulfate, hygromycin B, amikacin disulfate, sisomicin sulfate, tobramycin
sulfate, ribostamycin sulfate, and neamine hydrochloride were purchased from Santa Cruz
Biotechnology (Dallas, TX). Kanamycin sulfate was purchased from Genlantis (San Diego, CA).
Apramycin sulfate was purchased from Research Products International (Mount Prospect, IL).
Restriction enzymes, Phusion DNA polymerase, T4 DNA ligase and calf intestinal alkaline
phosphatase were purchased from New England Biolabs (Ipswich, MA). DNA purification and
concentration was performed using the DNA Clean & Concentrator Kit; and agarose gel DNA
extraction was performed using the Gel DNA Recovery Kit, both from Zymo Research (Irvine,
CA). Plasmid extractions were performed using the QIAprep Spin Miniprep Kit from Qiagen
(Valencia, CA). Oligonucleotides were obtained from Integrated DNA Technologies (Coralville,
IA). DNA sequencing was performed by Genewiz (South Plainfield, NJ). PCR reactions were
carried out using a Bio-Rad S1000 thermal cycler. Cell density and fluorescence measurements
were taken using a Molecular Devices SpectraMax M2 Multi-Mode Microplate Reader. Plasmid
and DNA sequence design and management was conducted using Vector NTI 10 (Life
Technologies). Chemically competent E. coli cells were prepared using the rubidium chloride
method.40 Standard molecular biological methods, protocols, reagents, and materials40 were used
for PCR, restriction enzyme digestion, ligation, transformation, selection of transformants,
agarose gel electrophoresis, gel extraction, and plasmid isolation unless otherwise specified.
Bacterial strains. E. coli DH5α and E. coli TOP10 were used for routine DNA cloning
and manipulation. E. coli SQ380 (E. coli MG1655/ΔrrnGADEHBC/prrnC-sacB41/ptRNA6741, S.
Quan and C. Squires, unpublished), in which all seven genomic rRNA operons have been deleted
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and replaced with a single plasmid-borne rRNA operon expressed from the sucrose counterselectable plasmid prrnC-sacB, was used as the starting point for construction of strains capable
of detecting ribosome inhibition by aminoglycoside antibiotics.
Bacterial culture. Routine liquid culture of E. coli DH5α and E. coli TOP10 for cloning
purposes was carried out in 2-5 mL of Luria-Bertani broth in sterile 15 mL conical tubes at 37 °C,
250 rpm overnight (12-16 h). Selection of E. coli DH5α and E. coli TOP10 transformants was
carried out on Luria-Bertani agar plates containing the appropriate antibiotic(s) at 37 °C
overnight (12-16 h). All cell growth and fluorescence assays were performed in sterile Cellstar
96-well deep well culture plates sealed with breathable sealing film, with one mL of LB media
per well and with appropriate concentrations of the necessary antibiotics (ampicillin - 100 μg/mL,
chloramphenicol - 35 μg/mL, kanamycin - 50 μg/mL, spectinomycin – 100 μg/mL),
anhydrotetracycline (1-100 ng/mL) and aminoglycoside (1-1024 μM).

Figure 2-3. PCR protocols used in this work
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General PCR conditions. Concentrations of template, primers, polymerase, dNTPs, and
buffer recommended by NEB for Phusion DNA polymerase were used unless otherwise
specified. We employed four types of PCR protocols to construct all fragments and all final
constructs not obtained by ligation: Protocol 1) PCR amplification of a single fragment with two
primers, Protocol 2) templateless (primer only) assembly with three primers, Protocol 3) two
fragment overlap extension PCR, and Protocol 4) COE-PCR (see Section 2.2.1 for an
explanation of this method). General PCR programs for each protocol are given in Figure 2-3
Enforced replacement by sucrose counterselection. To replace plasmid prrnC-sacB
(KanR, SucS) which is essential in E. coli SQ380 because it carries the only cellular copy of the
ribosomal RNA (rRNA) operon, with pRRSH2 (AmpR), pRRSH2-A1408G, or pRRSH2U1406A, we employed sucrose counterselection against the sacB (sucrose sensitivity gene)containing plasmid prrnC-sacB. E. coli SQ380 competent cells were grown in LB with
kanamycin and spectinomycin (essential tRNA-bearing plasmid ptRNA67 has a spectinomycin
resistance marker) and transformed with pRRSH2, pRRSH2-A1408G, or pRRSH2-U1406A.
Transformants were selected on LB agar with ampicillin and spectinomycin. One colony was
picked and grown in LB liquid with ampicillin and spectinomycin overnight, and plated on LB
agar with ampicillin, spectinomycin, and 5% (w/v) sucrose. Surviving colonies are resistant to
both ampicillin and sucrose, and have therefore gained pRRSH2 and lost prrnC-sacB.
Elimination of prrnC-sacB was verified by plasmid isolation and digestion of the resulting
plasmid mixture with PvuI, which has 3 recognition sites in prrnC-sacB but only a single site in
pRRSH2 and ptRNA67, and therefore gives a distinctive digestion pattern if prrnC-sacB is
present. This, rather than replica plate screening of surviving colonies for kanamycin sensitivity,
was done because pRRSH2-A1408G and pRRSH2-U1406A confer kanamycin resistance. The
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resulting strains - SH430 containing pRRSH2, SH386 containing pRRSH2-A1408G, and SH424
containing pRRSH2-U1406A – were used for transformation with plasmids carrying the Oribosome-based aminoglycoside detection systems (pSH3-KF through pSH14-KF).
Cell density and fluorescence assays. All cell density and fluorescence measurements
were taken in triplicate. 96-well culture plates (1 mL LB per well) with appropriate
concentrations of necessary antibiotics and aminoglycoside were inoculated 1:100 from a
saturated overnight liquid culture and allowed to grow for 18-24 h at 37 °C, 200 rpm shaking.
For cell density assays, 40 μL of sample was taken from each well, diluted 5-fold, and OD600
was measured by microplate reader. The OD600 of the original culture was calculated by
multiplying the reading by the dilution factor (5). For cell pellet fluorescence imaging, cells were
pelleted by centrifugation (4,000 g, 15 m, 4 °C) and the supernatant was decanted completely.
The underside of the plate was illuminated at 365 nm using an ultraviolet handheld lamp and
photographed with an 8 megapixel digital camera. For fluorescence quantification, cell pellets
were resuspended in 1 mL of ¼× Ringer’s solution (30.75 mM NaCl, 1.2 mM, KCl, 1.5 mM
CaCl2, pH 7.3-7.4), 200 μL of cells from each well were transferred to black 96-well plates, and
GFP fluorescence was measured (excitation = 395 nm, bandwidth = 9 nm; emission = 509 nm,
bandwidth = 15 nm). Fluorescence intensities were calculated as fluorescence/OD600 of the
sample minus fluorescence/OD600 of a sample of a non-GFP-expressing E. coli strain parental
to the strain being analyzed in order to correct for both cell density and E. coli auto-fluorescence.
Calculation of IC50, LD50 values and correlation analysis. Aminoglycoside IC50 values
were calculated by fitting fluorescence data obtained by incubating detection strains SH399 or
SH431 with aminoglycosides at concentrations from zero to the concentration that gives
maximal fluorescence signal to a sigmoidal equation by non-linear regression. The IC50 value is
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the concentration of aminoglycoside that gives half maximal fluorescence. Aminoglycoside
LD50 values were calculated by fitting OD600 data obtained by incubating the parent
aminoglycoside sensitive strain SH434 with aminoglycosides at concentrations from zero to 32
μM (or 1024 μM for neamine and hygromycin B) to a sigmoidal equation by non-linear
regression. The LD50 value is the concentration of aminoglycoside the gives 50% growth
inhibition (an OD600 value that is 50% of the maximal OD600 value). Correlation between IC50
values calculated from fluorescence data and either previously reported IC50 values obtained
from in vitro translation assays28 or LD50 values calculated from OD600 data were assessed by
linear regression analysis. The IC50 and LD50 values determined, and the results of linear
regression are summarized in Figure 2-23.
Construction of pRRSH2. Plasmid pKK353542 (11.9 kb), which contains the
constitutively expressed rrnB ribosomal rRNA operon, pMB1 origin of replication, and
ampicillin resistance marker, as well as 4.2 kb of non-essential DNA sequence, was used as the
starting point for construction of a simplified, refactored rrnB-expressing plasmid pRRSH2 (7.7
kb) (Figure 2-4), which also bears the ampicillin resistance marker, but contains the p15A origin
of replication. To construct pRRSH2, we employed concatamerizing overlap extension PCR
(COE-PCR, C. Melançon, unpublished), a de novo plasmid assembly method developed in our
group that is similar to the CPEC method.43 In COE-PCR, a circular plasmid is obtained by one
pot PCR assembly of linear fragments with short (15-25 bp) overlapping ends followed by
transformation of competent E. coli with the PCR assembly mixture. The 5.8 kb rrnB operon was
amplified as three fragments from pKK3535 using primer pairs pRRSH-rRNA1-up/pRRSHrRNA1-dn, pRRSH-rRNA2-up/pRRSH-rRNA2-dn, and pRRSH-rRNA3-up/pRRSH-rRNA3-dn.
The fragment containing the promoter and coding region of the ampicillin resistance marker was
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amplified from pKK3535 using primers pRRSH-AmpR-up and pRRSH-AmpR-dn. The fragment
containing the p15A origin of replication was amplified from pRepCM344 using primers pRRSHp15A-up and pRRSH-p15A-dn. The resulting five DNA fragments were assembled by COEPCR and the reaction mixture was concentrated using the Zymo Clean and Concentrator Kit, and
introduced into competent E.coli DH5ɑ cells. The final pRRSH2 construct was verified by
restriction mapping and sequencing. Primer information is given in table 2-1 below. The priming
region of each primer is underlined.

Table 2-1 Primers for constructing pRRSH2 plasmid
p15A origin of replication fragment sequence. Primer binding sites are underlined, and the p15A
origin region is shown in blue.
ATTACATGTGCGTCAGACCCCTTAATAAGATGATCTTCTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAAACGAAA
AAACCGCCTTGCAGGGCGGTTTTTCGAAGGTTCTCTGAGCTACCAACTCTTTGAACCGAGGTAACTGGCTTGGAGGAGCGCAG
TCACCAAAACTTGTCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAGACTAACTCCTCTAAATCAATTACCAGTGGCTGCT
GCCAGTGGTGCTTTTGCATGTCTTTCCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGACTGAACGG
GGGGTTCGTGCATACAGTCCAGCTTGGAGCGAACTGCCTACCCGGAACTGAGTGTCAGGCGTGGAATTAGACAAACGCGGCC
ATAACAGCGGAATGACACCGGTAAACCGAAAGGCAGGAACAGGAGAGCGCACGAGGGAGCCGCCAGGGGGAAACGCCTGG
TATCTTTATAGTCCTGTCGGGTTTCGCCACCACTGATTTGAGCGTCAGATTTCGTGATGCTTGTCAGGGGGGCGGAGCCTATGG
AAAAACGGCTTTGCCGCGGCCCTCTCACTTCCCTGTTAAGTATCTTCCTGGCATCTTCCAGGAAATCTCCGCCCCGTTCGTAAGC
CATTTCCGCTCGCCGCAGTCGAACGACCGAGCGTAGCGAGTCAGTGAGCGAGGAAGCGGAATATATCCTGTATCACATATTCT
GCTGACGCACCGGTGCAGCCTTTTTTCTCCTGCCACATGAAGCACTTCACTGACACCCTCATCAGTGCCAACATAGTAAGCCAG
TATACACTCCGCTAGCCCATGGAGATCTCTCGAGGGATCCGAAG
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Figure 2-4 Plasmid map of pRRSH2

Construction of pRRSH2-A1408G and pRRSH2-U1406A. Both plasmids were
constructed from pRRSH2. A 684 bp region of pRRSH2 containing the 16S rRNA A1408 and
U1406 sites was amplified in two fragments with the mutation site at the junction of the
fragments. In each case, the two fragments were joined by overlap extension PCR, the resulting
PCR product digested with BsrGI and XbaI, and cloned into pRRSH2 digested with the same
enzymes. For pRRSH2-A1408G (Figure 2-5), fragment 1 was amplified using primers pRRSH2A1408G-1 and pRRSH2-A1408G-2, and fragment 2 was amplified using primers pRRSH2A1408G-3 and pRRSH2-A1408G-4. For pRRSH2-U1406A, fragment 1 was amplified using
primers pRRSH2-A1408G-1 and pRRSH2-U1406A-2, and fragment 2 was amplified using
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primers pRRSH2-U1406A-3 and pRRSH2-A1408G-4. Introduction of the mutation into each
plasmid was verified by sequencing the cloned region of the plasmid containing it. The vector
map of pRRSH2-A1408G is given as an example. Primer information is given in the table 2-2
below. The A1408G and U1406A mutation sites are show in bold red in the primers that contain
them. The priming region of each primer is underlined.

Table 2-2 Primers for constructing pRRSH2-A1408G and pRRSH2-U1406A

Figure 2-5. Plasmid map of pRRSH2-A1408G
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Functional verification of pRRSH2-A1408G and pRRSH2 in E. coli SQ380. The ability of
pRRSH2-A1408G to confer aminoglycoside resistance was confirmed through a cell viability
assay. E. coli SQ380 was transformed with pRRSH2-A1408G; and prrnC-sacB was removed by
sucrose counter-selection, resulting in E. coli SH386. As a control, E. coli SQ380 was also
transformed with pRRSH2; and prrnC-sacB was removed by sucrose counter-selection, resulting
in E. coli SH430. The growth inhibition of these two strains by various kanamycin
concentrations was determined by inoculation of each strain (1:100 dilution of a saturated culture)
into ten 1 mL wells of a 96-well culture plate containing LB broth with specific concentrations of
kanamycin added (Figure 2-6), growth for 24 h at 37°C, 200 rpm shaking, and measurement of
the OD600. The results (Figure 2-6) clearly demonstrate that E. coli SH430, which has no 16S
rRNA aminoglycoside resistance mutation, experiences significant growth inhibition at 10 μM
kanamycin, and cannot survive at concentrations above 10 μM kanamycin; whereas E. coli
SH386, which has the A1408G mutation, shows no growth inhibition at any kanamycin
concentration tested, indicating that the mutation confers robust resistance to kanamycin at
concentrations as high as 500 μM.

Figure 2-6. OD600 readings of SH386 (A1408G, blue bars) and SH430 (wild-type, red bars)
grown in a range of kanamycin concentrations.
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Sequential construction of the reporter plasmid The final reporter plasmid, pSH6-KF,
was constructed in six steps:
1) Construction of pUC19-GFPuv, which contains the gfp-uv gene under control of the
PLtetO-1 promoter.
2) Optimization of the gfp-uv 5’-untranslated (5’-UTR) region through construction of a
five plasmid series pGBSH1-BCD2, pGBSH1-U2, pGBSH1-26.2, pGBSH1-pET, and pGBSH1pBEST.
3) Replacement of the ampicillin resistance marker with a chloramphenicol resistance
marker in pGBSH1-BCD2, the plasmid with the highest gfp-uv expression level from Step 2, to
give pGBSH3.
4) Insertion of the cassette containing tetR with orthogonal Shine-Dalgarno (O-SD)
sequence under control of medium strength promoter BBa_J23016 into pGBSH3 to give
pGBSH18.
5) Insertion of the cassette containing the orthogonal 16S rRNA (O-16S) under control of
the constitutive lpp promoter to give reporter plasmid pSH3-KF.
6) Optimization of the tetR and O-16S promoter strengths for use in E. coli SH386
through construction of an eleven plasmid series pSH4-KF through pSH14-KF.
Construction and testing of pUC19-GFPuv. This plasmid, which contains the gfp-uv gene
under control of the PLtetO-1 promoter/operator45, pMB1 origin of replication, and ampicillin
resistance marker was constructed from four fragments by COE-PCR. The PLtetO-1
promoter/operator was amplified from pSR26_2 (J. Tabor, unpublished) using primers
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pLTetO1N-up and pLtetO1-dn. The gfp-uv gene was amplified from plasmid pET101-GFP46
using primers pGFP-up and pCL-F2-dn. The pMB1 origin of replication was amplified from
pUC19 using primers pCL-F3-pMB1-up and pCL-F3-pMB1-dn. The ampicillin resistance
marker was amplified from pUC19 using primers pCL-F4-up and pCL-F4-dn. The resulting four
fragments were assembled by COE-PCR. The reaction mixture was concentrated using the Zymo
Clean and Concentrator Kit, and introduced into competent E.coli DH5ɑ cells. The final
construct was verified by restriction mapping and sequencing. Primer information is given in the
table 2-3 below. The priming region of each primer is underlined.

Table 2-3 Primers for constructing pUC19-GFPuv
gfp-uv fragment sequence. Primer binding sites are underlined, the gfp-uv coding region is
shown in blue with start and stop codons underlined, and the T7 terminator sequence is shown in
green.
GAAGGAATTCAGGAGCCCTTCACCATGAGTAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAATTAGATGG
TGATGTTAATGGGCACAAATTTTCTGTCAGTGGAGAGGGTGAAGGTGATGCAACATACGGAAAACTTACCCTTAAATTTATTT
GCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTCACTACTTTCTCTTATGGTGTTCAATGCTTTTCCCGTTATCCGGAT
CACATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATGTACAGGAACGCACTATATCTTTCAAAGATGACGG
GAACTACAAGACGCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTGATTTTAAAG
AAGATGGAAACATTCTCGGACACAAACTCGAATACAACTATAACTCACACAATGTATACATCACGGCAGACAAACAAAAGAAT
GGAATCAAAGCTAACTTCAAAATTCGCCACAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAAAATACTCCA
ATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTACCTGTCGACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGCGT
GACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACATGGCATGGATGAGCTCTACAAACTCGAGCACCACCAC
CACCACCACTGAAAGGGCGAGCTCAATTCGAAGCTTGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGT
ACCGGTCATCATCACCATCACCATTGAGTTTGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCG
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CTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGA
TATCCCGCAAGAGGCCCGG

Figure 2-7 Plasmid map of pUC19-GFPuv

E. coli DH5α transformed with pUC19-GFPuv displayed no fluorescence as determined by plate
reader fluorescence assay (see cell density and fluorescence assays section, above, for
experimental details). Reasoning that the lack of GFPuv expression was due to a non-optimal
chimeric 5’-untranslated region (5’-UTR) derived from fusion of 5’-UTRs from pSR26_2 and
pET101-GFP, we next constructed a series of five pUC19-GFPuv derivatives where the 5’-UTR
was varied.
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Construction of the pGBSH1 plasmid series. The pGBSH1 plasmid series was constructed by
replacement of the gfp-uv 5’-UTR on pUC19-GFPuv with 5 different 5’-UTRs. We chose three
5’-UTRs that were reported to be strong [BCD247, U248, pBEST (unpublished, from Addgene
#45784)] and two representing the intact 5’-UTRs associated with the GFPuv gene in pET101GFP (pET) and the PLtetO-1 promoter in pSR26_2 (26.2). Additionally, a T0 spacer sequence
was added between the ampicillin resistance gene and the PLtetO-1 portion to attempt to
minimize any polar effects on GFP expression. The T0 spacer was appended to the 5’ end of the
PLtetO-1 fragment. Construction of these plasmids was accomplished by five COE-PCR
reactions, each employing four fragments, three of which (pMB1 origin, ampicillin resistance
marker, T0 spacer-PLtetO-1) were identical in all five reactions, and one (the 5’-UTR-gfp-uv
fragment) of which was variable. The fragments containing the pMB1 origin and ampicillin
resistance marker were identical to those used in construction of pUC19-GFPuv.
The T0 spacer-PLtetO-1 fragment was constructed by three sequential PCR reactions in
which the product of the previous reaction was used as the template for the next reaction. The T0
spacer was amplified from plasmid pSR26_2 using primers pCL-F1-up and pCL-tetO1-dn-1. The
resulting PCR product was used as the template for a second round of PCR using primers pCLF1-up and pCL-tetO1-dn-2. The resulting PCR product was used as the template for a third
round of PCR using primers pCL-F1-up and pCL-tetO1-dn-3 to generate the final fragment.
The five 5’-UTR-gfp-uv fragments were constructed as follows: The pET 5’-UTR-gfp-uv
fragment was constructed in a single PCR reaction by amplification from plasmid pET101-GFP
using primers pCL-GFPuv-up-tetO1 and pCL-F2-dn. The U2 5’-UTR-gfp-uv, 26.2 5’-UTR-gfpuv, and pBEST 5’-UTR-gfp-uv fragments were each constructed by two sequential PCR
reactions in which the product of the first reaction (the gfp-uv-containing fragment, which was
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amplified from plasmid pET101-GFP), was used as the template for the second reaction. The U2
5’-UTR-gfp-uv fragment was constructed by amplification using primers pCL-u2-up-1 and pCLF2-dn; and the resulting PCR product used as the template for a second round of PCR using
primers pCL-u2-up-2-tetO1 and pCL-F2-dn. The 26.2 5’-UTR-gfp-uv fragment was constructed
by amplification using primers pCL-pSR26-up-1 and pCL-F2-dn; and the resulting PCR product
used as the template for a second round of PCR using primers pCL-pSR26-up-2-tetO1 and pCLF2-dn. The pBEST 5’-UTR-gfp-uv fragment was constructed by amplification using primers
pCL-45784-up-1 and pCL-F2-dn; and the resulting PCR product used as the template for a
second round of PCR using primers pCL-45784-up-2-tetO1 and pCL-F2-dn. The BCD2 5’-UTR
was constructed as a stand-alone fragment by templateless assembly using three primers (pCLBCD2-1-tetO1, pCL-BCD2-2, and pCL-BCD2-3). A gfp-uv-containing fragment was amplified
from pET101-GFP using primers pCL-F2-up-BCD2 and pCL-F2-dn; and the BCD2 5’-UTR and
gfp-uv-containing fragments were joined by overlap extension PCR and amplified using outside
primers pCL-BCD2-1-tetO1 and pCL-F2-dn to generate the final BCD2 5’-UTR-gfp-uv fragment.
Each of the five 5’-UTR-gfp-uv fragment variants was then assembled with the T0 spacerPLtetO-1, pMB1 origin, and ampicillin resistance marker fragments in a COE-PCR reaction.
Each reaction mixture was concentrated using the Zymo Clean and Concentrator Kit and
introduced into competent E.coli DH5ɑ cells. Each final construct was verified by restriction
mapping and sequencing. Primer information is given in the table 2-4 below. The priming region
of each primer is underlined. The vector map of pGBSH1-BCD2 is given as an example. The
figre 2-8 shows the constructs of the 5’-UTRs examined. The table 2-5 summarizing the 5’UTRs examined is given below.

45

Table 2-4 Primers for optimization of the gfp-uv 5’-untranslated (5’-UTR) region
T0 spacer fragment sequence. Primer binding sites are underlined, and the T0 spacer region is
shown in blue.
TGCTTGGATTCTCACCAATAAAAAACGCCCGGCGGCAACCGAGCGTTCTGAACAAATCCAGATGGAGTTCTGAGGTCATTACT
GGATCTATCAACAGGAGTCCAAGCGAGCTCGATATCAAAT
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Figure 2-8 Optimization of 5’UTR region of gfpuv gene

Table 2-5 Summary of the sequences of 5’UTR
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Figure 2-9 Plasmid map of pGBSH1-BCD2

pGBSH1 series functional assay. E. coli DH5α transformed with pGBSH1-BCD2,
pGBSH1-U2, pGBSH1-26.2, pGBSH1-pET, and pGBSH1-pBEST displayed a range of
fluorescences (Figure 2-10) as determined by plate reader fluorescence assays (see cell density
and fluorescence assays section, above, for experimental details), with pGBSH1-BCD2 resulting
in the highest fluorescence. Thus, pGBSH1-BCD2 was selected for further development.
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Figure 2-10 Cell pellet fluorescence and fluorescence quantification of pGBSH1 variants in
which the gfp-uv 5’-UTR has been altered.

Construction and testing of pGBSH3. After identification of plasmid pGBSH1-BCD2 as
the variant resulting in the highest fluorescence, the ampicillin resistance marker in pGBSH1BCD2 was replaced with a chloramphenicol resistance marker so that the resulting plasmid,
pGBSH3, could be co-transformed with pRRSH2-A1408G. A four fragment COE-PCR reaction
was employed to construct pGBSH3. Three of the fragments (BCD2 5’-UTR-gfp-uv, pMB1
origin, and T0-PLtetO-1) were identical to those used to construct pGBSH1-BCD2. The
fragment containing the chloramphenicol resistance marker was amplified from plasmid
pBKCM7b (Charles E. Melancon III, unpublished) using primers cat-pBKCM7b-up and catpBKCM7b-dn. After COE-PCR, concentration using a Zymo Clean and Concentrator Kit, and
transformation, the final construct was verified by restriction mapping and sequencing. Primer
information is given in the table 2-6 below. The priming region of each primer is underlined.
Retention of robust fluorescence by E. coli DH5α cells transformed with pGBSH3 was verified
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by plate reader fluorescence assays (see cell density and fluorescence assays section, above, for
experimental details).

Table 2-6 Primers for constructing pGBSH3
Chloramphenicol resistance marker fragment sequence is shown below. Primer binding sites are
underlined, the promoter sequence is shown in green, and the chloramphenicol acetyltransferase
coding region is shown in blue with start and stop codons underlined.
GGATCCAACTGCATTCAGAATAAATAAATCCTGGTGTCCCTGTTGATACCGGGAAGCCCTGGGCCAACTTTTGGCGAAAATGA
GACGTTGATCGGCACGTAAGAGGTTCCAACTTTCACCATAATGAAATAAGATCACTACCGGGCGTATTTTTTGAGTTGTCGAGA
TTTTCAGGAGCTAAGGAAGCTAAAATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGA
ACATTTTGAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTTAAAGACCGTA
AAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGAATGCTCATCCGGAATTACGTATGGCA
ATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACCCTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCG
CTCTGGAGTGAATACCACGACGATTTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCC
TATTTCCCTAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATTTAAACGTGG
CCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGGCGACAAGGTGCTGATGCCGCTGGCG
ATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGCAGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAG
GGCGGGGCGTAAGGCGCGCCATTTAAATGAAGTTCCTATTCCGAAGTTCCTATTCCTAGGGATTAAAAAGGCAACTTTATGCC
CATGCAACAGAAACTATAAAAAATACAGAGAATGAAAAGAAACAGATAGATTTTTTAGTTCTTTAGGCCCGTAGTCTGCAAAT
CCTTTTATGATTTTCTATCAAA
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Figure 2-11 Plasmid map of pGBSH3

Construction and testing of pGBSH18. A cassette containing the tetR gene with
orthogonal Shine-Dalgarno (O-SD) sequence (ATCCC) 49, 50 under control of medium strength
promoter BBa_J23106 (J. Christopher Anderson, unpublished) and containing the T1 terminator
was inserted into pGBSH3 to generate pGBSH18. A five fragment COE-PCR reaction was
employed to construct pGBSH18 (Figure 2-12). Three of the fragments (the BCD2 5’-UTR-gfpuv, chloramphenicol resistance marker, and T0-PLtetO-1) were identical to those used to
construct pGBSH1-BCD2 and pGBSH3. The pMB1 origin was amplified from pGBSH3 using
primers F3-up-tetRassem and pCL-F3-pMB1-dn.
The fragment containing O-SD-tetR (Figure 2-13) was constructed by three sequential
PCR reactions in which the product of the previous reaction was used as the template for the next
reaction. The tetR gene with T1 terminator was amplified from pSR26_2 using primers ptetR-151

KF-up and tetRassem1-dn-XmnI. The resulting PCR product was used as the template for a
second round of PCR using primers ptetR-2-KF-up and tetRassem1-dn-XmnI. The resulting PCR
product was used as the template for a third round of PCR using primers tetRassem1-up-XmnI
and tetRassem1-dn-XmnI to generate the final fragment. After COE-PCR, concentration using a
Zymo Clean and Concentrator Kit, and transformation, the final construct was verified by
restriction mapping and sequencing. Primer information is given in the table below. The priming
region of each primer is underlined. The O-SD sequence and ATG start codon are shown in bold
red in the primers that contain them. Retention of robust fluorescence by E. coli cells DH5α
transformed with pGBSH18 was verified as by plate reader fluorescence assays (see cell density
and fluorescence assays section, above, for experimental details). During the sequencing process,
we discovered two spontaneous mutations in the pMB1 origin (see below for locations). It is
unclear whether these mutations have any effect on plasmid copy number, but it is clear from
fluorescence assays that they do not interfere with replication in E. coli DH5α or gfp-uv
expression.

Table 2-7 Primers for constructing pGBSH18
Sequence of the tetR-T1 terminator fragment is shown below. Primer binding sites are
underlined, the tetR coding sequence is shown in blue, and the T1 terminator region is shown in
green.
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ATGATGTCTCGTTTAGATAAAAGTAAAGTGATTAACAGCGCATTAGAGCTGCTTAATGAGGTCGGAATCGAAGGTTTAACAAC
CCGTAAACTCGCCCAGAAGCTAGGTGTAGAGCAGCCTACATTGTATTGGCATGTAAAAAATAAGCGGGCTTTGCTCGACGCCT
TAGCCATTGAGATGTTAGATAGGCACCATACTCACTTTTGCCCTTTAGAAGGGGAAAGCTGGCAAGATTTTTTACGTAATAACG
CTAAAAGTTTTAGATGTGCTTTACTAAGTCATCGCGATGGAGCAAAAGTACATTTAGGTACACGGCCTACAGAAAAACAGTAT
GAAACTCTCGAAAATCAATTAGCCTTTTTATGCCAACAAGGTTTTTCACTAGAGAATGCATTATATGCACTCAGCGCAGTGGGG
CATTTTACTTTAGGTTGCGTATTGGAAGATCAAGAGCATCAAGTCGCTAAAGAAGAAAGGGAAACACCTACTACTGATAGTAT
GCCGCCATTATTACGACAAGCTATCGAATTATTTGATCACCAAGGTGCAGAGCCAGCCTTCTTATTCGGCCTTGAATTGATCATA
TGCGGATTAGAAAAACAACTTAAATGTGAAAGTGGGTCTTAAGGCATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGC
CTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGCCCTAGACCTAGGCGTTCGGCTGCGG
CGAGCGGTATCAGCTCACTCAAAG

Sequence of the pMB1 origin in pGBSH18 with spontaneous mutations marked in bold
underlined red. G at position 107 was mutated to C, and G at position 457 was mutated to A.
CGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGC
GAAACCCGACAGGACTATAAAGATACCAGCCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTG
CCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCT
CAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTAT
CCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATT
AGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGT
ATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCA
CCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTT

Figure 2-12 Plasmid map of pGBSH18
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Figure 2-13 The O-SD-tetR fragment
Construction and testing of pSH3-KF in E. coli DH5α. A cassette containing the
orthogonal 16S rRNA (O-16S) with orthogonal anti-Shine-Dalgarno (O-ASD) sequence
(TGGGG)

49, 50

was inserted into pGBSH18 to generate pSH3-KF, which contains all the

components of the orthogonal ribosome-based fluorescent reporter. A five fragment COE-PCR
reaction was employed to construct pSH3-KF.
Two of the fragments (the O-SD-tetR and pMB1 origin) were identical to those used to
construct pGBSH18. The chloramphenicol resistance marker fragment was amplified from
pBGSH18 using primers cat-pBKCM7b-up and pCAT-OKF-dn. A fragment containing T0PLtetO-1 and BCD2 5’-UTR-gfp-uv was also amplified from pGBSH18 using primers pGFPOKF-up and pCL-F2-dn.
The fragment containing the orthogonal 16S rRNA (O-16S) under control of the
reportedly strong lpp promoter (Plpp)
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was constructed by amplifying the Plpp-16S rRNA

cassette from plasmid pTrcSS1d-rrsBb (Shinichiro Shoji, unpublished) using upstream primer
pO16S-up and mutagenic downstream primer pO16S-KF-dn which was used to install the
orthogonal anti-Shine-Dalgarno (O-ASD) sequence. The strong terminator BBa_B001552 was
amplified from plasmid pSR26_2 using primers pB15-up and pB15-dn and appended to the 3’
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end of the Plpp-O-16S fragment by overlap extension PCR to attempt to minimize any polar
effects on other genes in the construct. After COE-PCR, concentration using a Zymo Clean and
Concentrator Kit, and transformation, the final construct was verified by restriction mapping and
sequencing. Primer information is given in the table 2-8 below. The priming region of each
primer is underlined. The lpp promoter and O-ASD sequences are shown in bold red in the
primers that contain them.
As expected, a nearly complete lack of fluorescence by E. coli DH5α cells transformed
with pSH3-KF was observed as determined by plate reader fluorescence assays (see cell density
and fluorescence assays section, above, for experimental details). However, as expected,
fluorescence of E. coli DH5α cells transformed with pSH3-KF could be recovered in a dosedependent manner by addition of various concentrations of anhydrotetracycline (ATC), which
binds to TetR and causes its dissociation from PLtetO-1 thereby relieving repression of
transcription (Figure 2-14).

Table 2-8 Primers for constructing pSH3-KF

Sequence of the lpp promoter - O16S fragment is shown below. Primer binding sites are
underlined, the lpp promoter is shown in green, the O-16S rRNA coding region is shown in blue,
and the O-ASD sequence is shown in red.
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ATTCTCAACATAAAAAACTTTGTGTAATACTTGTAACGCTAGATCCGGTAGCGATCGAAAGCGAAGCGGCACTGCTC
TTTAACAATTTATCAGACAATCTGTGTGGGCACTCGAAGATACGGATTCTTAACGTCGCAAGACGAAAAATGAATAC
CAAGTCTCAAGAGTGAACACGTAATTCATTACGAAGTTTAATTCTTTGAGCGTCAAACTTTTAAATTGAAGAGTTTG
ATCATGGCTCAGATTGAACGCTGGCGGCAGGCCTAACACATGCAAGTCGAACGGTAACAGGAAGAAGCTTGCTTCTT
TGCTGACGAGTGGCGGACGGGTGAGTAATGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGC
TAATACCGCATAACGTCGCAAGACCAAAGAGGGGGACCTTCGGGCCTCTTGCCATCGGATGTGCCCAGATGGGATTA
GCTAGTAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTAGCTGGTCTGAGAGGATGACCAGCCACACTGGAACT
GAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGC
CGCGTGTATGAAGAAGGCCTTCGGGTTGTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTC
ATTGACGTTACCCGCAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGGTGCAAGCGTTAA
TCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCAGATGTGAAATCCCCGGGCTCAACCTGGGAAC
TGCATCTGATACTGGCAAGCTTGAGTCTCGTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTAGAGATC
TGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACGAAGACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAG
GATTAGATACCCTGGTAGTCCACGCCGTAAACGATGTCGACTTGGAGGTTGTGCCCTTGAGGCGTGGCTTCCGGAGC
TAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAG
CGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAAGAACCTTACCTGGTCTTGACATCCACGGAAGTTTTCAGAGA
TGAGAATGTGCCTTCGGGAACCGTGAGACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTTGTGAAATGTTGGGTTAA
GTCCCGCAACGAGCGCAACCCTTATCCTTTGTTGCCAGCGGTCCGGCCGGGAACTCAAAGGAGACTGCCAGTGATAA
ACTGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGACCAGGGCTACACACGTGCTACAATGGCGCAT
ACAAAGAGAAGCGACCTCGCGAGAGCAAGCGGACCTCATAAAGTGCGTCGTAGTCCGGATTGGAGTCTGCAACTCGA
CTCCATGAAGTCGGAATCGCTAGTAATCGTGGATCAGAATGCCACGGTGAATACGTTCCCGGGCCTTGTACACACCG
CCCGTCACACCATGGGAGTGGGTTGCAAAAGAAGTAGGTAGCTTAACCTTCGGGAGGGCGCTTACCACTTTGTGATT
CATGACTGGGGTGAAGTCGTAACAAGGTAACCGTAGGGGAACCTGCGGTTGGATCATGGGGTACCTTAAAGAAGCGT
ACTTTGTAGTGCTCACACAGATTGTCTGATA

Figure 2-14 Cell pellet fluorescence and fluorescence quantification of E. coli DH5α cells
containing pSH3-KF grown in the presence of a range of anhydrotetracycline concentrations.
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Figure 2-15 Illustration of Plpp-O-16S-termintor fragment

Figure 2-16 Plasmid map of pSH3-KF
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Ribosome inhibition assay of kanamycin in E. coli SH391. We tested the ability of E. coli
SH386 cells transformed with pSH3-KF (referred to as E. coli SH391) to detect ribosome
inhibition by kanamycin. E. coli SH391 cells were grown in the presence of various
concentrations of kanamycin ranging from 0-500 μM and analyzed by fluorescence assay. E. coli
SH391 displayed strong fluorescence in the absence of kanamycin and only a modest (~50%)
increase in fluorescence when kanamycin was added. This result led us to construct and test
plasmids pSH4-KF – pSH14-KF in E. coli SH386.
Construction and testing of pSH4-KF - pSH14-KF in E. coli SH386. To attempt to
overcome the low sensitivity to kanamycin and high background fluorescence imparted by
pSH3-KF in E. coli SH386, we constructed a series of eleven pSH3-KF variants in which the
strengths of the two promoters controlling expression of tetR and O-16S rRNA were
combinatorially altered using synthetic constitutive promoters with characterized strengths (J.
Christopher Anderson, unpublished,). In addition to the original medium strength synthetic
promoter BBa_J23106 controlling tetR expression, strong promoter BBa_J23100 and weak
promoter BBa_J23115 were selected for use with tetR. In addition to the original lpp promoter
controlling O-16S rRNA expression, strong promoter BBa_J23100, medium strength promoter
BBa_J23108, and weak strength promoter BBa_J23114 were selected for use with O-16S rRNA.
The DNA sequence of these promoter were shown in table 2-10.
We first constructed two plasmids, pSH4-KF (Figure 2-17) and pSH5-KF, in which the
BBa_J23106 promoter controlling expression of tetR was replaced with strong promoter
BBa_J23100 and a weak promoter BBa_J23115, respectively. Promoter replacement was
accomplished by overlap extension PCR of two fragments amplified from pSH3-KF whose
junction encompassed each promoter to be inserted, digestion of both the resulting PCR product
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and pSH3-KF with unique restriction sites MfeI and NdeI, and ligation of the PCR product into
the vector. For construction of pSH4-KF, primer pSH4-KF-1 and mutagenic primer pSH4-KF-2
were used to amplify fragment 1; and mutagenic primer pSH4-KF-3 and primer pSH4-KF-4
were used to amplify fragment 2. For construction of pSH5-KF, primer pSH4-KF-1 and
mutagenic primer pSH5-KF-2 were used to amplify fragment 1; and mutagenic primer pSH5KF-3 and primer pSH4-KF-4 were used to amplify fragment 2. Plasmids pSH4-KF and pSH5KF were verified by sequencing the cloned region. Primer information is given in the table 2-9
below. The priming region of each primer is underlined.
To construct the remaining nine plasmid variants bearing strong (pSH6-KF, pSH9-KF,
pSH12-KF), medium (pSH7-KF, pSH10-KF, pSH13-KF), and weak (pSH8-KF, pSH11-KF,
pSH14-KF) strength promoters controlling expression of O-16S, we used a similar overlap
extension PCR strategy. Two fragments amplified from pSH3-KF whose junction encompassed
each promoter to be inserted were joined by overlap extension PCR. The PCR product bearing
strong promoter BBa_J23100 was constructed using primer pSH6-KF-1 and mutagenic primer
pSH6-KF-2 to amplify fragment 1; and mutagenic primer pSH6-KF-3 and primer pSH6-KF-4 to
amplify fragment 2. The PCR product bearing medium promoter BBa_J23108 was constructed
using primer pSH6-KF-1 and mutagenic primer pSH7-KF-2 to amplify fragment 1; and
mutagenic primer pSH7-KF-3 and primer pSH6-KF-4 to amplify fragment 2. The PCR product
bearing weak promoter BBa_J23114 was constructed using primer pSH6-KF-1 and mutagenic
primer pSH8-KF-2 to amplify fragment 1; and mutagenic primer pSH8-KF-3 and primer pSH6KF-4 to amplify fragment 2. Each of the resulting three PCR products was digested with unique
restriction enzymes PstI and SpeI and ligated into each pSH3-KF, pSH4-KF, and pSH5-KF
digested with the same enzymes to generate the nine final constructs pSH6-KF (Figure 2-18)
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through pSH14-KF. All nine plasmids were verified by sequencing the cloned region. Primer
information is given in the table below. The priming region of each primer is underlined.
Regions of the mutagenic primers containing promoter regions are show in bold red. Diagrams
of pSH4-KF and pSH6-KF are shown as examples. Summaries of the names, sequences, and
strengths (as measured by J. Christopher Anderson, unpublished) of the promoters used and of
the tetR and O-16S promoters found in each plasmid are summarized in two tables (table 2-10
and table 2-11) below. E. coli SH386 cells transformed with pSH4-KF – pSH14-KF displayed a
range of kanamycin concentration-dependent fluorescent phenotypes as determined by plate
reader fluorescence assays (see cell density and fluorescence assays section, above, for
experimental details). E. coli SH386 cells transformed with pSH6-KF (referred to as E. coli
SH391) displayed the most favorable properties: essentially no background fluorescence in the
absence of kanamycin, and a robust dose-dependent increase in fluorescence in response to
kanamycin (Figure 2-19). Thus, E. coli SH391 was selected for subsequent experiments.
Interestingly, the results are consistent with the lpp promoter being the weakest of the six
promoters tested. The full fluorescence quantification data are shown in Figure 2-20.
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Table 2-9 Primers for constructing pSH4-KF through pSH14-KF

Figure 2-17 Plasmid map of pSH4-KF

Figure 2-18 Plasmid map of pSH6-KF
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Table 2-10 Sequence of the promoters used in constructing pSH4-KF through pSH14-KF

Table 2-11 Promoter combinations of pSH3-KF through pSH14-KF
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Figure 2-19 Cell pellet fluorescence of initial detector strain E. coli SH391 (boxed in red), 11
additional strains with tetR and O-16S promoter strengths combinatorially altered (promoter
strengths are show on the left: +, very weak; ++, weak; +++, medium; ++++, strong), and E. coli
SH399, the strain with the best detection performance (boxed in green), in response to increasing
concentrations of kanamycin. Fluorescence quantification of E. coli SH391 and E. coli SH399 at
each of the 10 kanamycin concentrations tested is shown in the bar graphs to the right.

Figure 2-20 Fluorescence quantification of E. coli SH386 cells containing pSH3-KF – pSH14KF grown in the presence of a range of kanamycin concentrations.
63

3. Results and discussion
Ribosome inhibition assays of aminoglycosides in E. coli SH399. E. coli SH399, which
harbors detection plasmid pSH6-KF, was used to conduct ribosome inhibition assays using a
range of concentrations of twelve structurally diverse aminoglycosides – including 4,6disubstituted 2-deoxystreptamines (2-DOS) gentamicins, G418, sisomicin, tobramycin, and
amikacin; 4,5-disubstituted 2-DOS paromomycin, neomycin B, and ribostamycin; and atypical
2-DOS apramycin, hygromycin B, and neamine (Figure 2-1).In addition to kanamycin A, SH399
grown to stationary phase (18 h) in the presence of a range of concentrations of each
aminoglycoside was able to detect O-ribosome inhibition by nine of these compounds (Figure 221). The two compounds that failed to give a signal, G418 and hygromycin B, also caused
significant growth inhibition of SH399 (Figure 2-22), indicating that the A1408G 16S rRNA
mutation does not confer sufficient resistance to these compounds to allow survival of the
detector strain. This observation is consistent with previously reported levels of resistance
conferred by the A1408G mutation to a subset of the compounds examined,
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and for those

compounds that were detectable, the A1408G mutation confers resistance well above the
detection threshold (Figure 2-22).
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Figure 2-21 Cell pellet fluorescence of E. coli SH399 in response to increasing concentrations of
aminoglycosides. Kan, kanamycin A; Apr, apramycin; Neo, neomycin B; Paro, paromomycin;
Gen, gentamicins; Ami, amikacin; Nea, neamine; Rib, ribostamycin; Sis, sisomicin; Tob,
tobramycin.
The fluorescence dose-response patterns observed for SH399 treated with these 10
aminoglycosides were different for each compound (Figure 2-21, Figure 2-22) and appeared
upon qualitative inspection to correlate with previously reported compound potencies determined
by both in vitro translation assays26−30 and E. coli growth inhibition assays, 26, 28, 30 suggesting that
the O-ribosome reporter system may be useful for comparing aminoglycoside potencies. To
examine this possibility, we first compared IC50 values calculated from fluorescence data
obtained from aminoglycoside-treated SH399 with previously determined IC50 values of a
subset of six aminoglycosides (kanamycin A, neomycin B, paromomycin, gentamicins,
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ribostamycin, and tobramycin) measured through inhibition of translation in vitro.28 We found a
strong correlation (R2 = 0.97, Figure 2-23) between the two data sets, suggesting that IC50
values determined using the O-ribosome reporter assay are comparably accurate to those
determined using in vitro translation assays. Next, to test whether the fluorescence doseresponse patterns also correlate with inhibition of E. coli growth, we compared dose-dependent
growth inhibition (represented as LD50 values) of the parent aminoglycoside sensitive E. coli
strain SH434 with IC50 values calculated from fluorescence data obtained from aminoglycosidetreated SH399. While data obtained by the two methods correlated for a subset of the compounds
(apramycin, gentamicins, amikacin, ribostamycin, sisomicin, and tobramycin; R2 = 0.97, Figure
2-23), there was a lack of correlation between the two data sets for kanamycin A, neomycin B,
and paromomycin, and therefore between the two data sets as a whole (R2 = 0.40, Figure 2-23).
While the reason for the incomplete correlation between inhibition of E. coli growth and
fluorescence-derived IC50 values is unclear, we suggest that these inconsistencies are the result
of differences between the pleiotropic effects of differentially inhibiting the ribosome, whose
activity is required for synthesis of the entire E. coli proteome, on cell viability, and the effects of
differentially inhibiting the O-ribosome, which are restricted to the TetR-GFP output system.
Taken together, these results are consistent with the ability of the O-ribosome reporter system to
compare the potencies of aminoglycosides as ribosome inhibitors. Of the 10 compounds
examined, sisomicin was found to have the strongest ribosome inhibition activity, followed in
order of decreasing activity by gentamicins, neomycin B, paromomycin, tobramycin, amikacin,
ribostamycin, apramycin, kanamycin A, and neamine (Figure 2-22, 2-23). These results provide
a complete comparative assessment of the ribosome inhibiting potencies of these 10 compounds
that is consistent with previous reports of aminoglycoside potencies and structure − activity

66

relationships obtained through in vitro translation inhibition assays using subsets of these
compounds.26−30
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Figure 2-22 Fluorescence quantification (top row of graphs) and OD600 quantification (middle
row of graphs) of E. coli SH399 (pSH6-KF, pRRSH2-A1408G) cells grown in a range of
concentrations (0-500 μM) of each of the twelve aminoglycosides examined; and OD600
quantification (bottom row of graphs) of E. coli SH434 (pSH6-KF, pRRSH2) cells grown in a
range of concentrations (0-32 or 0-1024 μM, 2-fold serial dilutions) of each of the twelve
aminoglycosides examined. The scale of x and y axes is consistent for each row of bar charts.
Further discussion of these results is presented in the main article.

Figure 2-23 Analysis of the correlations between: (top table and graph) IC50 values previously
determined through in vitro translation assays 28 (column 1, x axis) and IC50 values determined
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from E. coli SH399-derived fluorescence data (column 2, y axis); (middle table and graph) LD50
values determined from growth inhibition assays of E. coli SH434 (column 1, x axis) and IC50
values determined from E. coli SH399-derived fluorescence data for the subset of 6 compounds
for which there was a statistically significant correlation (column 2, y axis); and (bottom table
and graph) LD50 values determined from growth inhibition assays of E. coli SH434 (column 1, x
axis) and IC50 values determined from E. coli SH399-derived fluorescence data for the full set
of 9 compounds (column 2, y axis). The 3 compounds that produced outlying data are labeled in
the graph. Note that neamine was excluded from the analysis due to its very weak ribosome
inhibition and growth inhibition activities. Further discussion of these results is presented in the
main article.
Interestingly, we also observed for some aminoglycosides that at drug concentrations
beyond those that give the peak response, fluorescence actually decreases and does so to varying
extents with different compounds (Figure 2-21, Figure 2-22). The effect was most pronounced
with neomycin B, paromomycin, and gentamicins; occurred to an intermediate extent with
sisomicin, tobramycin, and amikacin; occurred to a slight extent with kanamycin A and
apramycin; and was absent with ribostamycin and neamine. In the cases of paromomycin and
gentamicins, these decreases in fluorescence were accompanied by growth inhibition. These
results are consistent with previous structural and spectroscopic observations that neomycin B,
paromomycin, and gentamicin bind to and inhibit the ribosome at a second, lower affinity site in
helix 69 of the large ribosomal subunit.8,

10,12,15,18

In our system, binding to this site on the

pRRSH2-A1408G-derived ribosome would affect translation of both GFPuv and endogenous
proteins, leading to both a decrease in fluorescence and a loss of cell viability. When considered
together with previous work, our observations suggests that the O-ribosome reporter system can
identify, via dose-dependent fluorescence decrease at higher concentrations, aminoglycosides
that inhibit the ribosome by interacting with a secondary site such as H69, and that other
aminoglycosides in our panel that exhibit this phenomenon may also bind to H69 or to another
secondary site. Examination of the X-ray crystal structures of neomycin B, paromomycin, and
gentamicin C1a bound to H6915 reveals conserved contacts between the C-1 and C-3 amines of
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the 2-DOS core, which are present in all aminoglycoside structures, and residues 1921−1923 of
the 23S rRNA, leaving open the possibility that other aminoglycosides may interact with H69.
Experiments to test the binding of aminoglycosides in our panel to H69 are currently underway
in our laboratory.
To further explore the capabilities of the system and attempt to develop a strain that can
detect O-ribosome inhibition by hygromycin B and G418, we introduced the U1406A mutation
into pRRSH2. Mutations at position 1406 confer an aminoglycoside resistance spectrum distinct
from that of A1408G, including resistance to G418 (U1406A) 32 and hygromycin B (U1406C).33
We tested the ability of strain SH431 carrying this mutation and reporter plasmid pSH6-KF
grown to stationary phase (24 h) in the presence of a range of concentrations of each
aminoglycoside to detect O-ribosome inhibition by the same set of 12 aminoglycosides. As
anticipated, SH431 was able to detect O-ribosome inhibition by both G418 and hygromycin B
(Figure 2-24) as well as kanamycin A and gentamicins (Figure 2-25). We observed significant
growth inhibition and a lack of signal by SH431 in the presence of the remaining eight
compounds, indicating that the U1406A mutation is unable to confer resistance to these
compounds. Dose response patterns observed for SH431 treated with the four compounds for
which fluorescence could be observed indicate that, among these, gentamicins are the most
potent ribosome inhibitors, followed by G418 and hygromycin B, and with kanamycin A being
the least potent (Figure 2-25, 2-26). IC50 values calculated from the O-ribosome- based
fluorescence assay correlated with LD50 values of the parent aminoglycoside sensitive E. coli
strain SH434 for three of the compounds (gentamicins, G418, hygromycin B; R2 = 0.997, Figure
2-26), but not for kanamycin A, as was the case with SH399.
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Figure 2-24 Cell pellet fluorescence of E. coli SH431 in response to increasing concentrations of
G418, geneticin (G418); Hyg, hygromycin B.

Figure 2-25 Fluorescence quantification (top row of graphs) and OD600 quantification (bottom
row of graphs) of E. coli SH431 (pSH6-KF, pRRSH2-U1406A) cells grown in a range of
concentrations (0-500 μM) of G418, hygromycin, kanamycin, and gentamicins. The scale of x
and y axes is consistent for each row of bar charts.
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Figure 2-26 Analysis of the correlations between: (top table and graph) LD50 values determined
from growth inhibition assays of E. coli SH434 (column 1, x axis) and IC50 values determined
from E. coli SH431-derived fluorescence data for the subset of 3 compounds for which there was
a statistically significant correlation (column 2, y axis); and (bottom table and graph) LD50
values determined from growth inhibition assays of E. coli SH434 (column 1, x axis) and IC50
values determined from E. coli SH431-derived fluorescence data for the full set of 4 compounds
(column 2, y axis). The compound that produced outlying data is labeled in the graph.

4. Conclusion
In summary, we have created engineered E. coli strains that can directly detect and
quantify ribosome inhibition at the A-site by a variety of structurally distinct aminoglycosides
with high sensitivity and essentially no background. The fluorescence dose−response patterns we
observed for the aminoglycosides tested correlate with their reported ribosome inhibiting
potencies, demonstrating that our system can be used to determine the relative potencies of
aminoglycosides as ribosome inhibitors. The observation that compounds known to act by
binding to H69 show dose-dependent fluorescence decrease at high concentrations suggests that
our system can also report on compound secondary binding modes. We have also demonstrated
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that the selectivity of each strain for detection of specific aminoglycosides-even those with high
structural similarity such as gentamicin and G418-can be controlled by employing 16S rRNA
mutations that confer distinct resistance profiles. We believe that the strains developed here
provide a powerful new tool for assaying and studying ribosome inhibition by aminoglycosides
and other ribosome inhibitors in the context of live bacterial cells and will find broad
applicability in drug discovery endeavors.
We envision that the O-ribosome reporter strategy described here can be used to assess
structure−activity relationships of synthetic aminoglycoside analogs in high-throughput, to detect
and quantify aminoglycosides in natural product extracts, and to detect activity of
aminoglycoside biosynthetic enzymes, as was recently done with a target-based β-lactam
antibiotic detection system.53 We suggest that our strategy can be extended to specifically detect
ribosome inhibition by compound classes acting at other 16S rRNA binding sites such as
streptomycin, kasugamycin, spectinomycin, tetracyclines, tuberactinomycins, and pactamycins1
by employing 16S rRNA resistance mutations specific to each compound class. Furthermore,
with the recent development of a functional ribosome in which the 16S and 23S rRNAs are
tethered,
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our strategy may be extended to detect ribosome inhibition by compounds targeting

the 23S rRNA such as macrolides, thiostrepton, avilamycin, and others. 1 Mutation of the Oribosome A-site in the strains described here to mimic the A-site of other bacteria (e.g.,
Mycobacteria or other pathogens) or human mitochondria may also allow estimation of
aminoglycoside potency against these bacteria, or toxicity to human cells, respectively.
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CHAPTER 3. EXTENDING THE DETECTION SYSTEM TO SENSE
OTHER RIBOSOME SMALL SUBUNIT INHIBITORS AND LARGE
SUBUNIT INHIBITORS.
1. Introduction
Chapter 2 has described the development of detection and quantification system for
ribosome inhibition by aminoglycoside antibiotics, specifically by the 2-DOS aminoglycosides.
The system is highly sensitive to detect a panel of 12 2-DOS aminoglycosides with essentially no
signal background. The assay can be done by conventional over-night culturing, and the
fluorescence signal can be visualized directly by eyes or can be quantified by fluorometer or
microplate reader. These advantages make the system more amenable to use in any laboratory
than any in vitro methods so far. 1 The engineered E.coli strains are non-pathogenic and easy to
culture and distributed. These advantages make the system safer to use in any biological lab than
the commonly used in vivo methods. 1 Thus, the system is considered to be an accurate and userfriendly method to directly detect and quantify ribosome inhibitions. It should be a powerful new
tool to greatly promote the development and discover of new drugs and drug leads. Therefore,
extending the detection ability of the 2-DOS aminoglycosides detection system to sense other
class of ribosome inhibitors is critical to promote the application of the system. To prove our Oribosome controlled-fluorescence reporter system can be a general platform for detecting
ribosome inhibition by a variety of structurally and mechanistically distinct drug classes acting
on ribosome, we tend to extend the system to sense other ribosome small subunit inhibitors
which bind to different sites of 16S rRNA compared to 2-DOS aminoglycosides, and ribosome
large subunit inhibitors. Eventually we hope to develop a complete O-ribosome controlled-

81

fluorescence reporter system that can directly detect and quantify ribosome inhibition by any
small molecules targeting the ribosome.
To extend the current 2-DOS aminoglycosides detector system to sense other ribosome
small subunit inhibitors, functional drug resistant rRNA mutations which can protect the
ribosome from drug binding and yet support the cell survival and growth must be found and
introduced into the pRRSH2 plasmid. As a proof of concept, we choose three antibiotics which
have distinct structure characteristics and modes of actions as our target compounds to test.
These three compounds are spectinomycin, streptomycin and kasugamycin. Spectinomycin (see
structure in Figure 3-1) is aminocyclitol class antibiotics and it is widely used as a safe drug to
treat gonorrhea infection all over the world. It kills bacterial pathogens by binding to the helix 45
(h45) region of 16S rRNA and consequently inhibits the translocation of tRNA during the
translation. 2 Its mechanism of action had been well characterized by genetic experiments 3 and
crystallography.

2

The spectinomycin-bound ribosome structure shows there are many polar

contacts between rRNA and spectinomycin ring A and ring B (See crystal structure in Figure 19). Resistance mutation on rRNA has been isolated from various bacterial pathogens. 4, 5, 6 The
mutation C1192U on 16S rRNA can confer high spectinomycin resistance and it doesn’t cost
fitness lost on ribosome activity. 7 Streptomycin (see structure in Figure 3-1) is a non-2-DOS
aminoglycoside antibiotic. It is one of the oldest antibiotics found in the world. It was first used
as an effective treatment for tuberculosis until the drug resistance mutations emerge. It acts by
binding to the helix 18 region of the 16S rRNA and consequently block the income tRNA to the
decoding site (A-site) of the ribosome. Biochemical studies and crystallography show that
streptomycin not only has many polar contacts with 16S rRNA, but also has some polar contacts
with ribosomal protein S128 (see crystal structure in Figure 3-2). Therefore, resistance mutations
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had been isolated from both 16S rRNA9,

10

and ribosomal protein S12.

11

Among all these

resistance mutations, C912U on 16S rRNA might be best one to be applied onto our system since
it can confer high resistance to streptomycin and cost little fitness lost.

9

Kasugamycin (see

structure in Figure 3-1) is also a non-2-DOS aminoglycoside antibiotic with a unique chemical
structure. It was originally isolated from Japan in 1965 to prevent growth of a fungus causing
rice blast disease. Kasugamycin acts by binding to the helix 24 region of 16S rRNA and
consequently disrupt the interaction of initiator tRNA and the start codon at the P-site. 12 The
kasugamycin-bound ribosome crystal structure shows there are relatively fewer polar contacts
between the drug and ribosome (see crystal structure in Figure3-2). Resistant mutation of
kasugamycin on 16S rRNA had been isolated in the laboratory. 13 A794G was reported to confer
high resistance to kasugamycin and cost little fitness lost. 14 The differences of chemical structure
and mode of action among these three antibiotics make them perfect representatives for ribosome
small subunit inhibitors.

Figure 3-1 Chemical structures of spectinomycin, kasugamycin and streptomycin.
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A.

B.

Figure 3-2 Crystal structure of drug bound ribosome. (A) Crystal structure showing interactions
between streptomycin (yellow) with Thermus thermophilus 30S ribosomal subunit; (B) Crystal
structure showing interactions between kasugamycin (cyan) with E.coli 30S ribosomal subunit.

To extend the ribosome inhibition detector system to sense ribosome large subunit
inhibitors, the complete orthogonal ribosome system must be developed and integrated into our
O-ribosome controlled-fluorescence reporter system. The current detector system harbors an O16S rRNA which is sensitive to drug binding. The O-16S rRNA share the wild type 23S rRNA
with the wild type 16S rRNA. Therefore the 23S rRNA cannot be separated to be sensitive to the
drug binding, while it has to support the cell growth at the same time. Thanks to the recent
development of synthetic biology, an artificial ribosome (RiboT) which has the large subunit and
small subunit permanently linked together during the translation had been development by
Mankin lab and Jewett Lab recently. 15 By doing circularly permutation on the 23S rRNA, the
original 5’end and 3’ end of 23S rRNA had been closed with a short nucleotide linker and
multiple new ends were opened. These newly opened ends were screened by linking to the h44
of 16S rRNA to check the ribosome activity. The one that has the best activity was chosen for
further optimization. This engineered ribosome with tethered subunits can be a perfect tool for
orthogonal translation since the tethered 23S-16S rRNA won’t interact with wild type 23S rRNA
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or 16S rRNA. What’s more amazing is that the RiboT can actually support the cell survival and
growth without the wild type ribosome. The RiboT, therefore, is the perfect tool to help us
extend the current ribosome inhibition detection system to sense inhibitors that target the
ribosome large subunit.
To develop the O-ribosome-based detector system to sense ribosome large subunit
inhibitors, the RiboT was used as the drug resistant ribosome to support cell growth. By
introducing specific drug resistant mutation onto the RiboT, the RiboT should be protected from
drug binding (Figure 3-3). The current sensor plasmid pSH6-KF was modified by replacing the
chloramphenicol acetyl transferase gene with DHFR and the O-16S rRNA fragment with
orthogonal 23S-16S-5S (O-23S-16S-5S) rRNA operon. The chloramphenicol acetyl transferase
can chemically modified chloramphenicol class antibiotics which target the large subunit of the
ribosome, therefore it needs to be replaced. The O-23S-16S-5S rRNA operon harboring the OASD sequence which only translation the tetR gene will be the drug sensitive ribosome to
process the signal from drug binding. As a proof of concept, we chose three antibiotics which
have distinct structure characteristics and modes of actions as our target compounds to test the
system development. These three compounds are erythromycin, lincomycin and linezolid (See
structures in Figure 3-4).

Figure 3-3. Schematic showing the ribosome large subunit inhibitor sensor
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Figure 3-4. Chemical structures of erythromycin, lincomycin and linezolid.
Erythromycin is the classic macrolide antibiotic and it was discovered in 1952. It is
commonly used to treat respiratory tract infections, skin infections, chlamydia infections,
and syphilis. Erythromycin has a 14-member macro-lactone ring with a desosamine and a
cladinose side chains attach to it. It has been used as a scaffold to generate many erythromycinderived antibiotics, such as azithromycin, dirithromycin, telithromycin and so on.

16

Erythromycin’s mode of action is promoting early drop-off of nascent peptide by blocking the
nascent peptide exit tunnel. Its binding site had been well characterized by biochemical studies17
and crystallography. 18 (See crystal structure in Figure 3-5) The mutation A2058G on 23S rRNA
can disrupt the drug binding and lead to drug resistance. Lincomycin is a classic lincosamide
antibiotic that has a different chemical structure to macrolide antibiotics. It has a broader
spectrum of antimicrobial antivity than macrolides. Lincomycin acts by binding to the PTC of
ribosome and inhibiting the peptide-bond formation. 18 The same mutation A2058G can disrupt
the drug binding and confer resistance to lincomycin. Linezolid is a synthetic compound first
developed by Pharmacia and Upjohn Company in 1990s. It belongs to the oxazolidinone class
compound and is widely used to treat gram-positive bacterial infections. Currently it is thought
that the linezolid binds to the similar site as lincomycin at the PTC and consequently inhibit the
peptide-bond formation (See crystal structure in Figure 3-5). 19 However, the A2058G mutation
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doesn't confer obvious resistance to linezolid. Therefore its mechanism of action should be
different from lincomycin. Currently the investigation of linezolid mode of action is still actively
going. The mutation G2576U was found in many species of bacterial to confer high linezolid
resistance. 20 This indicates G2576U mutation should cost little fitness lost and it should be good
to use in our system. These three drugs should be good representative for ribosome larger subunit
inhibitors due to their chemical structure and their mechanism of actions.

A.

B.

Figure 3-5 Crystal structure of erythromycin-bound (A) and linezolid-bound (B) ribosome.
With the complete ribosome inhibition detector system in hand, we set out to apply the
system to examine ribosome inhibition by novel small molecules. There are several potential
directions for applying our detector system. For instance, the detector can be used to detect and
screen natural product extracts for ribosome inhibitors. It can also be used as the reporter system
to evolve ribosome inhibitor biosynthetic enzymes in vivo. One of the simplest applications of
the system is to screen compound libraries and study drug structure-activity relationships (SAR).
As a proof of principle, we applied the system to screen a set of spectinomycin analogs and study
the SAR from our sensing results. Although the fact that spectinomycin has been accepted as
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general safe drug, it lacks antimicrobial activity against most of the clinically pathogens. With
the increase of the drug resistance, developing new drugs from current drug arsenal is still the
most promising approach. With an excellent safety index, spectinomycin could be a promising
drug scaffold to modify. According to the spectinomycin-bound ribosome structure (Figure 1-9),
ring A and ring B of spectinomycin have many polar contacts with rRNA and ribosomal protein
S12. However, ring C presents fewer interactions with ribosome. Especially the 3’ ketone group
of ring C has a large space to be engineered from the structure. We therefore applied our detector
system to screen the ribosome inhibition of a set of 20 spectinomycin analogs and 36 glycoside
analogs. Our results show that the O-ribosome controlled reporter system can rapidly evaluate
the compound potency and study the SAR. Our efforts on extending the detection system should
prove that the O-ribosome controlled reporter system can be able to detect and quantify any
small molecules that target the bacterial ribosome.
2. Experimental procedures
General. Most materials used for work described in this chapter have already been
mentioned in the experimental procedures section of Chapter 2. Kasugamycin, erythromycin,
lincomycin (U-10149A), linezolid and trimethoprim were purchased from Santa Cruz
Biotechnology (Dallas, TX). Spectinomycin, streptomycin and trimethoprim were purchased
from Genlantis (San Diego, CA).
Bacterial strains. Most of the bacterial strains used for work described in this chapter
have been mentioned in the experimental procedures section of Chapter 2. E. coli SQ171fg (E.
coli MG1655/ΔrrnGADEHBC/prrnC-sacB/ptRNA67, gift from Alexander S. Mankin)

15

, in

which the ybeX gene which is a putative Mg21/Co21 transporter has a nonsense mutation, and
the rpsA gene which encodes ribosomal protein S1 has a miscoding mutation. With these two
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mutations the SQ171fg has shorter doubling time with the RiboT as the sole ribosome to support
cell growth. It was used as the starting point for construction of strains capable of detecting
ribosome inhibition by large subunit inhibitors.
Bacterial culture. All of the bacterial culture methods used for work described in this
chapter have been mentioned in the experimental procedures section of Chapter 2. The working
concentration of trimethoprim used in this work is 80µg/mL.
PCR conditions. All of the PCR conditions used for work described in this chapter have
been mentioned in the experimental procedures section of Chapter 2. Gibson assembly reaction
condition is the same as the reported method. 21
Enforced replacement by sucrose counterselection. The enforced replacement method
was already described in the experimental procedures section of Chapter 2.
Cell density and fluorescence assays. The methods for measuring cell density and
fluorescence intensity was already described in the experimental procedures section of Chapter 2.
Construction of E.coli strain SH435. Since ptRNA67 plasmid in SQ380 has a
spectinomycin resistance gene which can pump out the spectinomycin and streptomycin from the
cell, it has to be replaced so that the cell can be a suitable host for building spectinomycin and
streptomycin detectors. The ptRNA67 was replaced by ptRNA70 (Michael O’ Connor,
unpublished work) which has a tetracycline resistance gene instead of spectinomycin resistance
gene. The ptRNA70 was transformed into SQ380 and the transformants were grown on
tetracycline LB agar plate. After passage the cells for one generation, a few colonies were
verified to lose the ptRNA67 by phenotypic screening. The resulting strain harbors two plasmids:
prrnC-sacB and ptRNA70, and it is named SH435 (Figure 3-6)
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.
Figure 3-6 Construction of E.coli ∆7 strain SH435.
Construction of pRRSH2 plasmid series with various mutations. Various rRNA mutations
that were reported to confer high resistance to specific antibiotics were introduced into pRRSH2
plasmid, respectively. The construction of each plasmid was described below:
1) Construction of pRRSH2-C1192U and pRRSH2-C1192U/A2058G. pRRSH2-C1192U
was constructed from pRRSH2. A 2636 bp region of pRRSH2 containing the 16S rRNA
C1192U site was amplified in two fragments with the mutation site at the junction of the
fragments. The two fragments were joined by overlap extension PCR, the resulting PCR product
digested with BsrGI and BamHI, and cloned into pRRSH2 digested with the same enzymes.
Fragment 1 was amplified using primers pRRSH2-A794G-1 and pRRSH2-C1192U-2, and
fragment 2 was amplified using primers pRRSH2-C1192U-3 and pRRSH2-A794G-4. pRRSH2C1192U/A2058G was constructed from pRRSH2-C1192U by Gibson Assembly. Four fragments
were amplified by PCR. The 16S rRNA fragment was amplified using primers pRRSH-rRNA1up and pRRSH-rRNA1-dn. The 3.6 kb 23S rRNA fragment was amplified as two fragments from
pRRSH2 using primer pairs pRRSH-rRNA2-up/pRiboT-A2058G-2, and pRiboT-A2058G3/pRRSH-rRNA3-dn. The mutation site was generated at the overlap part of these two fragments.
The fragment containing the p15A origin of replication and ampicillin resistance marker was
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amplified from pRRSH2 using primers pRRSH-AmpR-up and pRRSH-p15A-dn. The resulting
four DNA fragments were assembled by Gibson Assembly. Introduction of the mutation into
each plasmid was verified by sequencing the cloned region of the plasmid containing it. The
vector map of pRRSH2-C1192U/A2058G is given as an example (Figure 3-7). Primer
information is given in the table 3-1 below. The C1192U and A2058G mutation sites are show in
bold red in the primers that contain them.

primer name

sequence (5' -3' )

pRRSH2-A794G-1

TCCCAACGCGTAAACGCCTTGC

pRRSH2-C1192U-2

GGTGGGGATGATGTCAAGTCATCATG

pRRSH2-C1192U-3

GACTTGACATCATCCCCACCTTCCTC

pRRSH2-A794G-4

CAGATCGCTGAGATAGGTGCCTCAC

pRRSH-rRNA1-up

TTTGGTTGAATGTTGCGCGGTC

pRRSH-rRNA1-dn

CGGTGTCCTGGGCCTCTAGAC

pRRSH-rRNA2-up

TCTAGAGGCCCAGGACACCGCCCTTTCACGGCGGTAACAG

pRiboT-A2058G-2

GTCTTCCCGTCTTGCCGCGG

pRiboT-A2058G-3

CCGCGGCAAGACGGGAAGACCCCGTGAAC

pRRSH-rRNA3-dn

AGCTGCTTTCCTGATGCAAAAACG

pRRSH-AmpR-up

CGTTTTTGCATCAGGAAAGCAGCTGATATCAGACGTCAGGTGGCACTTTTC

pRRSH-p15A-dn

CCGCGCAACATTCAACCAAAATTACATGTGCGTCAGACCC

amplicon
size (bp)

template

440

pRRSH2

2537

pRRSH2

2116

pRRSH2-C1192U

2322

pRRSH2

1373

pRRSH2

1970

pRRSH2

Table 3-1 Primers for constructing pRRSH2-C1192U and pRRSH2-C1192U/A2058G
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Figure 3-7 Plasmid map of pRRSH2-C1192U/A2058G
2) Construction of pRRSH2-A794G/C1192U/A2058G and pRRSH2-C912U/C1192U/
A2058G. Both plasmids were constructed from pRRSH2-C1192U/A2058G. A 2636 bp region of
pRRSH2-C1192U/A2058G containing the 16S rRNA A794 and C912 sites was amplified in two
fragments with the mutation site at the junction of the fragments. In each case, the two fragments
were joined by overlap extension PCR, the resulting PCR product digested with BsrGI and
BamHI, and cloned into pRRSH2 digested with the same enzymes. For pRRSH2A794G/C1192U/A2058G, fragment 1 was amplified using primers pRRSH2-A794G-1 and
pRRSH2-A794G-2, and fragment 2 was amplified using primers pRRSH2-A794G-3 and
pRRSH2-A794G-4. For pRRSH2-C912U/C1192U/A2058G, fragment 1 was amplified using
primers pRRSH2-A794G-1 and pRRSH2-C912U-2, and fragment 2 was amplified using primers
pRRSH2- C912U-3 and pRRSH2-A794G-4. Introduction of the mutation into each plasmid was
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verified by sequencing the cloned region of the plasmid containing it. Primer information is
given in the table 3-2 below. The A794G and C912U mutation sites are show in bold red in the
primers that contain them.

primer name

sequence (5' -3' )

amplicon
size (bp)

template

pRRSH2-A794G-2

GCAAACAGGATTAGATGCCCTGGTAGTC (with pRRSH2-A794G-1)

843

pRRSH2-C1192U/A2058G

pRRSH2-A794G-3

GACTACCAGGGCATCTAATCCTGTTTGC (with pRRSH2-A794G-4)

2142

pRRSH2-C1192U/A2058G

pRRSH2-C912U-2

GGCCGCAAGGTTAAAACTTAAATGAATTGACGGGG
(with pRRSH2-A794G-1)

850

pRRSH2-C1192U/A2058G

pRRSH2- C912U-3

CAATTCATTTAAGTTTTAACCTTGCGGCC (with pRRSH2-A794G-4)

1295

pRRSH2-C1192U/A2058G

Table 3-2 Primers for constructing pRRSH2- A794G/C1192U/A2058G and pRRSH2C912U/C1192U/A2058G

Construction of detector strains SH442, SH446 and SH456. pRRSH2-C1192U, pRRSH2C1192U/A2058G, pRRSH2-A794G/C1192U/A2058G and pRRSH2-C912U/C1192U/A2058G
were transformed into SH435 respectively. prrnC-sacB plasmid was cured out by sucrose
counter-selection. One of the four plasmids, pRRSH2-C1192U, was fail to support the cell
survival and growth. This is proven by the failure of curing out prrnC-sacB in SH435. Three
E.coli

strains

SH438

(pRRSH2-C1192U/A2058G

&

ptRNA70),

SH445

(pRRSH2-

C912U/C1192U/A2058G & ptRNA70) and SH470 (pRRSH2-A794G/C1192U/A2058G &
ptRNA70) were generated as the host for the detector strains. The spectinomycin detector strain
was constructed by transforming the best reporter plasmid pSH6-KF (described in chapter 2) into
SH438, resulting in the detector strain SH442. The streptomycin detector strain was constructed
by transforming pSH6-KF into SH445, resulting in SH446. The kasugamycin detector strain was
constructed by transforming pSH6-KF into SH470 and resulting in SH456.
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Optimization of the streptomycin detector. To improve the sensitivity of the streptomycin
detector SH446, the same approach described in chapter 2 was used to combinatorial adjust
promoter strength of tetR and O-16S genes. pSH3-KF - pSH14-KF (except pSH6-KF) were
transformed into SH445 and the resulting strains were subjected to ATC titration assay (Figure
3-8) and ribosome inhibition assay with a range of streptomycin concentrations (Figure 3-9).
Fluorescence intensity was determined by plate reader. The strain SH475 shows the best
sensitivity against streptomycin and therefore was chosen as the final streptomycin detector
strain.

Figure 3-8 Cell pellet fluorescence showing ATC titration of 12 streptomycin detector starins.
The tetR and O-16S promoter strengths have been combinatorially altered (promoter strengths
are show on the left: +, very weak; ++, weak; +++, medium; ++++, strong).
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Figure 3-9 Cell pellet fluorescence showing ribosome inhibition assay by a range of
streptomycin concentrations with 12 streptomycin detector strains. The tetR and O-16S promoter
strengths have been combinatorially altered (promoter strengths are show on the left: +, very
weak; ++, weak; +++, medium; ++++, strong). The best streptomycin detector strain SH475 was
boxed in red.

Construction of pRiboT2-A2058G and pRiboT2-G2576U. pRiboT2-A2058G and
pRiboT2-G2576U were constructed from poRiboT215 (purchased from addgene). First, the
orthogonal anti-Shine-Delgano sequence (O-ASD) on the RiboT of poRiboT2 was replaced with
WT-ASD sequence. A 1374 bp region of poRiboT2 containing the ASD sequence was amplified
in two fragments with the mutation site at the junction of the fragments. The two fragments were
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joined by overlap extension PCR, the resulting PCR product digested with PvuII and XbaI, and
cloned into poRiboT2 digested with the same enzymes. Fragment 1 was amplified using primers
poRiboT-WTSD-1 and poRiboT-WTSD-2, and fragment 2 was amplified using primers
poRiboT-WTSD-3 and pRRT-3'16S-dn. Replacement of the ASD sequence was verified by
sequencing. The resulting plasmid is called pRiboT2. Then, the A2058G and G2576U mutations
were introduced into pRiboT2 respectively. For introducing A2058G into pRiboT2, A 1374 bp
region of pRiboT2 containing the A2058 site was amplified in two fragments with the mutation
site at the junction of the fragments. Primer pairs poRiboT-WTSD-1/pRiboT-A2058G-2 and
pRiboT-A2058G-3/pRRT-3'16S-dn were used to amplified fragment 1 and 2 respectively. The
two fragments were joined by overlap extension PCR, the resulting PCR product digested with
PvuII and XbaI, and cloned into pRiboT2 digested with the same enzymes. For introducing
G2576U, the same approach used for introducing A2058G was used except the primer pairs are
poRiboT-WTSD-1/pRiboT-G2576U-2 and pRiboT-G2576U-3/pRRT-3'16S-dn. Introduction of
the mutation into each plasmid was verified by sequencing the cloned region of the plasmid
containing it. The vector map of pRiboT2-A2058G is given as an example in figure 3-10. Primer
information is given in the table 3-3 below. The ASD sequence, A2058G and G2576U mutation
sites are show in bold red in the primers that contain them.

primer name

sequence (5' -3' )

poRiboT-WTSD-1

CCAAGGCGCTTGAGAGAACTCGGG

poRiboT-WTSD-2

TTTAAGGTAAGGAGGTGATCCAACCGCAGGTTC

poRiboT-WTSD-3

TTGGATCACCTCCTTACCTTAAAGAAGCGTAC

pRRT-3'16S-dn

amplicon
size (bp)

template

1325

poRiboT2

456

poRiboT2

TCACAACCCGAAGATGTTTCTTTCG

pRiboT-A2058G-2

GTCTTCCCGTCTTGCCGCGG (with poRiboT-WTSD-1)

426

pRiboT-A2058G-3

CCGCGGCAAGACGGGAAGACCCCGTGAAC (with poRiboT-WTSD-4)

1352

pRiboT-G2576U-2

CGACGTTCTAAACCCAGCTAGCGTACCACTTTAAATGGCGAAC
(with poRiboT-WTSD-1)

958
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pRiboT2
pRiboT2

pRiboT-G2576U-3

GTTCGCCATTTAAAGTGGTACGCTAGCTGGGTTTAGAACGTCG
(with poRiboT-WTSD-4)

843

Table 3-3 Primers for constructing pRiboT2, pRiboT2-A2058G and pRiboT2-G2576U

Figure 3-10 Plasmid map of pRiboT2-A2058G
Construction and function testing of pSH18. pSH18 is the modified version of pSH6-KF.
The chloramphenicol resistance gene on pSH6-KF was replaced with DHFR gene (Jeff Tabor,
unpublished). And the mutated pMB1 origin of replication was replaced with ColE1 origin
(Chad Melancon, unpublished). The 23S rRNA and 5S rRNA were integrated into the
downstream of the O-16S rRNA to make it a complete rRNA operon with the same anti-ShineDelgano sequence as the pSH6-KF. The plasmid map of pSH18 is shown in Figure 3-13. To
construct pSH18, two intermediate plasmids, pRRSH2b (Figure 3-11) and pSH18BB (Figure 3-
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12), were construct by Gibson assembly. For pRRSH2b, in which two restriction enzyme cutting
sites (SpeI and NotI) were introduced at both ends of the rRNA operon, a four-fragment Gibson
assembly was performed to build the plasmid. The fragment 1, O-16S rRNA fragment (1802 bp),
was amplified from pSH6-KF by primers pSH15-16S-up and SH16-O16S-dn. Fragment 2, part
of the 23S rRNA fragment (2226bp), was amplified from pRRSH2 by primers SH16-rRNA2-up
and pRRSH-rRNA2-dn. Fragment 3, another part of 23S rRNA and 5S rRNA (1809 bp), was
amplified from pRRSH2 by primers pRRSH-rRNA3-up and SH16-rRNA3-dn. Fragment 4, the
ampicillin resistance marker and p15A origin fragment (1974 bp), was amplified from pRRSH2
by primers pRRSH2b-AmpR-up and pRRSH2b-p15a-dn. The 4 fragments then were used for
assembling pRRSH2b by Gibson assembly. For pSH18BB, a three-fragment Gibson assembly
was performed to build the plasmid. The fragment 1, gfpuv and tetR fragment (2093 bp), was
amplified from pSH6-KF by primers SH16Backbone-up and pSH18-tetR-dn. Fragment 2, the
ColE1 origin fragment (689 bp), was amplified from pBKCM7b (Chad Melancon, unpublished)
by primers pSH18-ColE1-up and pSH18-ColE1-dn. Fragment 3, the DHFR fragment (675 bp),
was amplified from pSH16BB (unpublished work) by primers pSH18-DHFR-up and
SH16Backbone-dn-2. The three fragments were then assembled by Gibson assembly to build
pSH18BB. Both pRRSH2b and pSH18BB were digested by SpeI and NotI. The 5649 bp
fragment from pRRSH2b and the 3287 bp fragment from pSH18BB were purified and ligated by
T4 ligase. The resulting plasmid pSH18 was verified by restriction enzyme digestion and
sequencing on the key components (tetR promoter, O-16S rRNA promoter and origin of
replication). Primer information is given in the table 3-4 below. The priming region of each
primer is underlined. The O-ASD sequence is shown in bold red in the primers that contain them.
The NotI and SpeI sites are shown in bold blue.
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primer
name

sequence (5' -3' )

amplicon
size (bp)

template

1802

pSH6-KF

pSH15-16S-up

TACCCCATTGATCCAACCGCAGG

SH16-O16S-dn

GCAGGGTCGCACTAGTTTGTGCATGC

SH16-rRNA2-up

CCTGCGGTTGGATCAATGGGGTACCTTAAAGAAGCGTACTTTGTA
GTGC (used with pRRSH-rRNA2-dn)

2226

pRRSH2

SH16-rRNA3-dn

GCGGCCGCAGCTGCTTTCCTGATGCAAAAACG(used with pRRSHrRNA3-up)

1809

pRRSH2

pRRSH2b-AmpRup

TTTGCATCAGGAAAGCAGCTGCGGCCGCAGACGTCAGGTGGCACT
TTTCGGG

1974

pRRSH2

pRRSH2b-p15adn

GCATGCACAAACTAGTGCGACCCTGCATTACATGTGCGTCAGACC
C

SH16Backboneup

CGGATCTAGCGTTACAAGTAGCTAGCACTGTACCTAGGACTGAGCT
AGCCGTCAATCGTG

2093

pSH6-KF

pSH18-tetR-dn

CTCACGTTAAGGGATTTTGGTCATGATTAAGACCCACTTTCACATT
TAAGTTG

pSH18-ColE1-up

TCATGACCAAAATCCCTTAACGTGAGTTTTCG

689

pBKCM7b

pSH18-ColE1-dn

CATATGGGCCGCGTTGCTGGCG

pSH18-DHFR-up

CCAGCAACGCGGCCCATATGTGCTTGGATTCTCACCAATAAAAAA
C

673

pSH16BB

SH16Backbonedn-2

CTAGCTACTTGTAACGCTAGATCCGATAGTTTAGCGGCCGCATTC

Table 3-4 Primers for constructing pRRSH2b and pSH18BB

ColE1 origin of replication fragment sequence. Primer binding sites are underlined, and the
ColE1 origin region is shown in blue.
TCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATC
CTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTAC
CAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACC
ACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGT
GTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCC
CAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCATTGAGAAAGCGCCACGCTTCCCGAAGGGAGA
AAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTA
TCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAA
AAACGCCAGCAACGCGGCCCATATG
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Figure 3-11 Plasmid map of pRRSH2b

Figure 3-12 Plasmid map of pSH18BB
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Figure 3-13 Plasmid map of pSH18

The pSH18 was then transformed into SH437fg which is constructed from SQ171fg
(Mankin, RiboT paper) by replacing the prrnC-sacB with pRiboT2-A2058G to construct the
ribosome large subunit inhibitor detector strain. The resulting strain is called SH440 and it was
tested with its ability to detect ribosome inhibition by erythromycin. The SH440 cells were
grown in the presence of various concentrations of erythromycin ranging from 0-500 μM and
analyzed by fluorescence assay (method was described in chapter 2). The SH440 cells were also
grown in the presence of various concentrations of ATC to test the functionality of O-ribosome
controlled tetR-gfpuv genetic circuit. SH440 displayed no sensitivity to erythromycin and low
sensitivity to ATC (Figure 3- 14). The results suggest that the O-ribosome controlled tetR-gfpuv
genetic circuit is detuned. The copy of tetR is much more than the copy of gfpuv mRNA, leading
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to an insensitive O-ribosome controlled tetR-gfpuv genetic circuit. Further optimizations need to
be done to tune the sensitivity of SH440.
Optimization of ribosome large subunit inhibitor detector strain. To tune the sensitivity
of the current detector strain SH440, we applied the same approach described previously (both
on this chapter and chapter 2) to combinatorially adjust promoter strength of tetR gene and O16S rRNA gene. According to ribosome inhibition assay and ATC titration assay results from
SH440, the expression of tetR gene needs to be down-regulated. Therefore, we first replace the
O-16S rRNA promoter from BBa_J23100 (strong strength) to BBa_J23108 (medium strength),
BBa_J23114 (weak strength) and lpp promoter (original promoter for O-16S rRNA, chapter 2),
respectively. Three intermediate plasmids pRRSH2b-J23018, pRRSH2b-J23114 and pRRSH2blpp were constructed by Gibson assembly. The construction procedure is similar to the pRRSH2b
assembly except the O-16S rRNA fragments were amplified from different templates with the
same primer pair (pSH15-16S-up/ SH16-O16S-dn). For pRRSH2b-J23018, the O-16S rRNA was
amplified from pSH7-KF. For pRRSH2b-J23114, the O-16S rRNA was amplified from pSH8KF. For pRRSH2b-lpp, the O-16S rRNA was amplified from pSH3-KF. The pRRSH2b-J23018,
pRRSH2b-J23114 and pRRSH2b-lpp were digested by SpeI and NotI, respectively. The 5649bp
fragments from the three digestion reactions were purified and ligated to the digested pSH18BB
(3426 bp, described in previous paragraph), respectively. The resulting plasmids were named
pSH29 (with BBa_J23108), pSH30 (with BBa_J23114) and pSH20 (with lpp). The plasmids
summary can be found in table 3-5 below.
To further tune down the expression of tetR gene, we replace the tetR gene promoter
from BBa_J23106 (medium strength) to BBa_J23115 (weak strength) on pSH18, pSH29, pSH30
and pSH20. The intermediate plasmid pSH22BB was constructed by using similar approach as
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pSH18BB except the gfpuv and tetR fragment was amplified from pSH5-KF with the same
primer pair (SH16Backbone-up/pSH18-tetR-dn). The pSH22BB was then digested with SpeI and
NotI. The resulting 3287 bp fragment was purified and ligated to the 5469 bp digested fragments
from pRRSH2b, pRRSH2b-J23108, pRRSH2b-J23114 and pRRSH2b-lpp, respectively. The four
new plasmids were named pSH24 (BBa_J23100 on O-16S rRNA), pSH26 (BBa_J23108 on O16S rRNA), pSH28 (BBa_J23114 on O-16S rRNA) and pSH22 (lpp on O-16S rRNA). The
plasmids summary information is shown in the table 3-5.
tetR
O-16S
plasmid promoter
strength
promoter
strength
pSH18 BBa_J23106 medium (0.47) BBa_J23100 strong (1.0)
pSH29 BBa_J23106 medium (0.47) BBa_J23108 medium (0.51)
pSH30 BBa_J23106 medium (0.47) BBa_J23114 weak (0.10)
pSH20 BBa_J23106 medium (0.47) lpp
ND
pSH24 BBa_J23115 weak (0.15)
BBa_J23100 strong (1.0)
pSH26 BBa_J23115 weak (0.15)
BBa_J23108 medium (0.51)
pSH28 BBa_J23115 weak (0.15)
BBa_J23114 weak (0.10)
pSH22 BBa_J23115 weak (0.15)
lpp
ND
Table 3-5 Plasmid summary information
The seven new plasmids, pSH29, pSH30, pSH20, pSH24, pSH26, pSH28 and pSH22,
were transformed into SH437fg. The resulting strains and the SH440 were tested with their
sensitivity on erythromycin and ATC. One of the strains SH460, which harbors the plasmid
pSH26 (see table 3-5 for more information), exhibit best sensitivity against erythromycin (Figure
3-15). It was used as the detector strain to detect ribosome inhibition by lincomycin.
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Figure 3-14 Cell pellet fluorescence showing ATC titration of 8 large subunit unit inhibitors
detector strains. The tetR and O-16S promoter strengths have been combinatorially altered
(described previously). The original detector strain SH440 is boxed in green and the optimized
detector strain SH460 is boxed in red.
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Figure 3-15 Cell pellet fluorescence showing ribosome inhibition assay by a range of
erythromycin concentrations with the 8 detector strains. The tetR and O-16S promoter strengths
have been combinatorially altered (described previously). The original detector strain SH440 is
boxed in green and the optimized detector strain SH460 is boxed in red.

Direct measurement of ribosome inhibition by spectinomycin analogs. A set of 16
spectinomycin analogs and 20 glycoside analogs with unknown potency were subjected to
ribosome inhibition assay by spectinomycin detector SH442. All the 36 compounds were
synthesis by Throson Lab (Jon Throson, unpublished). For the 16 spectinomycin analogs, the 3’
ketone group was replaced with different substituents. The 20 glycoside analogs are the
intermediate compounds with the opening ring B. A certain amount of H2O was added to each
compound to make it 100µM stock solution. Each compound was diluted to a range of 12
concentrations from 0µM to 500µM. The ribosome inhibition fluorescence assay was performed
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as previously described (chapter 2). Calculation of IC50 value was done previously described
method (chapter 2). The chemical structures of the 36 compounds were shown in the Figure 3-16.

Figure 3-16 Chemical structures of spectinomycin analogs used in this work
Continue on next page
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Figure 3-16 Chemical structures of spectinomycin analogs used in this work

3. Results and discussion
Extending the aminoglycosides detector to other ribosome small subunit inhibitors. By
introducing different rRNA mutations which can prevent drug binding on rRNA and yet don’t
cause serious fitness lost onto the WT rRNA operon of the detector system, the aminoglycoside
antibiotics detector system can be easily extended to detect spectinomycin and kasugamycin. The
ribosome inhibition assay shows that spectinomycin has very strong anti-ribosome activity based
on our results. The fluorescence signal shows up as early as 10 µM spectinomycin and the
detector strain displays robust fluorescence intensity in higher concentrations (Figure 3-17). This
is consistent with previously reporter results.

22
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Despite spectinomycin possess high anti-

ribosome activity, it still lacks anti-bacterial activity against most of the clinical pathogens due to
the efflux system in these bacterial. Because of the high safe index of spectinomycin, chemical
structure modification is worthwhile to pursue in order to improve the drug potency. Compare to
spectinomycin, kasugamycin displays very low ribosome inhibition activity based on our assay
result. This correlates with the fact that kasugamycin has generally fewer polar contacts with
rRNA than other ribosome inhibitors from crystal structures..

Figure 3-17 Cell pellet fluorescence of E. coli SH442, SH475 and SH456 in response to
increasing concentrations of target molecules.

Unlike spectinomycin and kasugamycin detector strains, streptomycin detector displays
very low sensitivity against streptomycin after direct transfer of sensing plasmid pSH6-KF. We
hypotheses that is due to the C912U mutation can cause more fitness lost than other mutations
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we used and consequently cause disequilibrium effect on the O-ribosome controlled tetR-gfpuv
circuit. The ATC titration assay result proves our hypothesis (Figure 3-18). Four of the five
detector strains (SH399, SH431, SH442, SH456 and SH446) begin to show fluorescence signal
between 1 – 10 ng/mL ATC. However, the streptomycin detector strain displays weaker
sensitivity to ATC with the fluorescence signal comes up as early as 25ng/mL. The streptomycin
detector strain also displays generally lower fluorescence intensity than other 4 detectors.

Figure 3-18 Bar graph figures showing the ATC titration of 5 detector strains. SH399 and
SH431 are the 2-DOS aminoglycosides detectors (Chapter 2); SH442 is spectinomycin detector;
SH456 is the kasugamycin detector; SH446 is the streptomycin detector. Note that the scales of y
axis of the bar graphs are not the same due to the difference of the signal intensity between each
detector.
These results promote us to down-regulate the expression of tetR for optimizing the
sensitivity of streptomycin detector. The optimized streptomycin detector strain SH475 displays
good sensitivity against streptomycin and it is capable to detect as low as 20µM streptomycin in
vivo (Figure 3- 17). One interesting phenomenon we observed is that streptomycin only at 50 µM
concentration can always inhibit the detector strains’ growth, which resulting in a strange biphase signal pattern. The detector strains can still grow in the presence of high concentration
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streptomycin. We speculate this is due to the incomplete protection of WT rRNA by the C912U
mutation. According to the streptomycin-ribosome co-crystal structure8, there are several polar
contacts between the streptomycin and ribosomal protein S12. Genetic studies also show that
mutation on S12 can lead to high resistance level to streptomycin. 11 Therefore, the single rRNA
mutation C912U may not be able to completely block the streptomycin binding to ribosome and
consequently affect the growth of the streptomycin detector strains.
Extending the ribosome inhibition detector to ribosome large subunit inhibitors. Thanks
to the development of RiboT, our ribosome inhibition detector system can be extended to sense
ribosome large subunit inhibitor as well. We therefore set to develop a complete ribosome
inhibition detection system capable of sensing any small molecules that target ribosomal RNA.
With the drug-resistant RiboT supporting cell growth, the 23S-16S-5S rRNA operon with an
orthogonal ASD can be completely orthogonal to the RiboT protein synthesis machinery. We
first used the same promoter combination of tetR and O-16S rRNA from pSH6-KF to build the
ribosome large subunit inhibitor detector strain. We found that the resulting strain SH440 is
insensitive to erythromycin and shows weak sensitivity to ATC. Therefore we applied the same
strategy to tune down the production of tetR by altering the promoter strength of tetR and O-16S
rRNA. The best detector strain SH460 harboring pSH26 exhibits good sensitivity against
erythromycin with the signal comes up as early as 80µM erythromycin (Figure 3-19). The signal
displays a bi-phase pattern similar to the streptomycin detector’s signal against streptomycin. We
speculate this is also due to the incomplete protection of the RiboT with the single rRNA
mutation A2058G. The detector strain SH460 was then used to detection the ribosome inhibition
by lincomycin, a different class of ribosome inhibitor compared to erythromycin. The signal of
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ribosome inhibition by lincomycin shows up later than erythromycin (Figure 3-19), suggesting
lincomycin has lower anti-ribosome activity than erythromycin.
To prove the ribosome large subunit inhibitor detection system is extendable, we
introduced another mutation G2576U which is reported to confer high resistance to linezolid
onto the RiboT and try to extend to detector to sense linezolid. The resulting strain SH493
harboring pSH26 is capable to detect linezolid with good sensitivity. The ribosome inhibition
assay shows that linezolid has a very weak anti-ribosome activity compared to erythromycin and
lincomycin. The fluorescence signal shown at 100µM – 200µM (Figure 3-19). This is probably
due to E.coli strains have intrinsic efflux system to dilute the linezolid concentration. 23

Figure 3-19 Cell pellet fluorescence of E. coli SH460 and SH493 in response to increasing
concentrations of target molecules. (Black box means growth inhibition)
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The results we show here have proven our O-ribosome controlled reporter system can be
extended to detect ribosome inhibition by large subunit inhibitors. By integrating the complete
orthogonal translation system RiboT into our detection system, we were able to free the 23S
rRNA from supporting cell growth and assign it as the regulatory element to sense drug binding.
Our results suggest that the large subunit detector should be able to detect macrolide antibiotics
and lincosamide antibiotics with decent signal intensity. To prove the system can be extended to
sense other large subunit inhibitors targeting different region of rRNA, we introduced another
rRNA mutation G2576U into the RiboT and turned the system to sense linezolid. In principle,
the detector system is able to sense any ribosome large subunit inhibitors that bind to the 23S
rRNA.
Determination of ribosome inhibition by spectinomycin analogs. Technologies that can
rapidly assess the relative potency or bioactivity of new compounds in high-throughput manner
are critical for drug development. Here we show that the use of O-ribosome controller
fluorescence reporter system can easily determine the ribosome inhibition activity of a
spectinomycin compound library. The assay is done in conventional over-night culturing and the
signal can be visualized by eyes or quantified by microplate reader. The detector strain is a nonpathogenic E.coli and is easy to distribute. We suggest the O-ribosome controller fluorescence
reporter system can be a general tool for direct measurement of ribosome inhibition by small
molecules.
The ribosome inhibition assays of spectinomycin analogs by detector SH442 show that 3
of the spectinomycin analogs, SP05, SP28 and SP33, have higher or comparable anti-ribosome
activity compared to the parent compound spectinomycin (SP01) (Figure 3-20 ). By looking at
the structure, these three compounds have an amine substituent at the 3’ position of ring C in the
112

‘S’ configuration. Although this 3’ amine substituent seems to be important in the ribosome
inhibition effect, the other two compounds (SP17 and SP23) which also have a 3’ amine
substituent don’t exhibit obvious ribosome inhibition activity. These results suggest that the side
chain attached to the 3’ amine substituent also play important roles in ribosome binding. By
looking at the assay result, the stereochemistry of the 3’ substituent can affect the ribosome
binding as well. SP02/SP03 and SP05/SP29 are two set of compounds with a different
stereochemistry at the 3’ substituent. The ‘S’ configuration of the compound (SP02 and SP29)
displays higher anti-ribosome activity than the ‘R’ configuration of the compound (SP03 and
SP05).

Figure 3-20 Cell pellet fluorescence of E. coli SH442 in response to increasing concentrations of
spectinomycin analogs. (Black box with ‘X’ means outlier data)
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For the ribosome inhibition assay of glycoside analogs, none of the 20 compounds
display good anti-ribosome activity (Figure 3-21). By looking at the spectinomycin-ribosome
crystal structure, the broken ring B of these glycoside analogs disrupts most of the polar contacts.
One of the compound SPG10 shows growth inhibition to the detect strain at high concentrations.
This suggests the SPG10 has other target sites other than the h34 of 16S rRNA. One interesting
result we observed is the SPG8 which is the intermediate of SP14 has higher anti-ribosome
activity than SP14. This result suggests that the 3’ substituent group restores the ribosome
binding even though the broken ring B abolished some polar contacts.

Figure 3-21 Cell pellet fluorescence of E. coli SH442 in response to increasing concentrations of
glycoside analogs. (Red box indicated growth inhibition.)
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These results demonstrate the O-ribosome controlled reporter system is capable to
determine ribosome inhibition activity by small molecules with unknown activity. It is also able
to be a target-based screening technique to screen inhibitors that target specific region of
ribosome. We suggest the O-ribosome controlled reporter system can be a pre-screening tool to
rapidly find the compound with good anti-ribosome activity at the early stage of drug
development.
4. Conclusion
To conclude this chapter, we have extended our O-ribosome controlled fluorescence
reporter system to detect and quantify ribosome inhibition by a variety of ribosome small subunit
inhibitors and ribosome large subunit inhibitors. In principle, the current detectors systems
should be able to detect and quantify ribosome inhibition by any small molecules targeting
ribosome. The detector system can be also considered as target-based screening tool. Different
detector strains developed in this work can be used to detect and classified a variety of antibiotics
classes. The key to extend the O-ribosome controlled fluorescence reporter system to detect
different ribosome inhibitors is to find suitable rRNA mutation that can block drug binding and
yet cause less fitness lost on ribosome activity. Nowadays more and more drug-bound ribosome
structures have been solved. It is much easier to locate the ribosome inhibitors binding site with
the structure information. We envision that by using saturation mutagenesis approach on the drug
binding region of rRNA, mutations that can fit into our detection system should be found for
every ribosome inhibitor.
By showing the possibility of extending the detection ability of the system, we greatly
promote the system towards diverse applications. We have proposed several potential
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applications in chapter 2. The simplest application is to use our system as the target-based
screening tool to evaluate potency of compound library. As a proof of concept, we applied the
spectinomycin detector strain SH442 to evaluate the potency of a set of spectinomycin analogs.
The assay can be done within 24 hours and is doable in every bio-lab. Our ribosome inhibition
assay shows that 3 of the spectinomycin analogs have higher or comparable anti-ribosome
activity to their parent compound. It is worthwhile to conduct future pharmacological test on
these three compounds. SAR was also studied based on our ribosome inhibition assay. A 3’
amine substituent at ring C of spectinomycin has the potential to increase the anti-ribosome
activity. The opening ring B of spectinomycin will greatly reduce the anti-ribosome activity.
Overall, we have shown the generality of our in vivo ribosome inhibition detection system and
the possibility of applying the system to screen a compound library. We suggest that our
detection system can be a general tool for early stage screening of ribosome inhibitors.
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CHAPTER 4. DIRECTED EVOLUTION OF RIBOSOMAL RNA
VARIANT TO EXAMINE THE INTERACTIONS BETWEEN
AMINOGLYCOSIDE ANTIBIOTICS AND RIBOSOME.
1. Introduction
Chapter 2 and chapter 3 have described the development and extension of O-ribosome
controlled fluorescence reporter system which can be used to detect and quantify ribosome
inhibition by a variety of ribosome inhibitors in vivo. We have proven the feasibility of using the
system to screen a spectinomycin compound library in a more efficient way, which is one of the
potential applications we proposed. The parallel ribosome system with similar copy number
represents a unique feature of our system and we have shown the success of using the Oribosome as a detector for ribosome inhibition. We then set out to further utilize the system as a
tool to study drug-ribosome interactions by fully altering the rRNA sequence at the drug binding
sites. With the advantage of having two similar populations of ribosome in the cell, we envision
that interesting new mutations on rRNA will be found and interactions between ribosome
inhibitors and mutated ribosomes could lead us to new inside of ribosome inhibition. The new
founding may lead us to develop better antibiotics in the future.
The ribosome is a highly evolved macro-molecule with many conserved functional
domains across all the species in bacterial kingdom. Although ribosome is consisted of rRNAs
and ribosomal proteins, only rRNAs had been proven to perform catalytic function1. This
correlates with the fact that rRNA sequence is highly resistant to alteration. As a result, nature
chose the ribosome as the major target for antimicrobial agents due to its essentiality to cell
survival and fragility to alterations. A large effort had been made in the past to search for
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functional mutations on rRNA2. Most of them aimed to characterize the role of the target rRNA
sequence in protein synthesis3, 4. Most of the mutations were shown to be lethal to cell and
therefore their functions cannot be examined5, such as interactions between ribosome inhibitors
and drug binding site. Previous reports had described an O-ribosome based system to study the
impact of deleterious mutations on 16S rRNA to protein synthesis6. The system was able to
systematically study the rRNA sequence of important regions for ribosome catalytic activity.
However, the O-ribosome based system was used in WT E.coli strains and therefore the presence
of genomic rRNA operons limits the system to studying ribosome inhibition by antimicrobial
agents.
To develop the O-ribosome based system to study ribosome inhibition, the ratio between
WT ribosome and O-ribosome is crucial. It has been suggested that the population of mutated
ribosome has large impact on its drug-resistance property. For instance, the U1406A mutation
can cause high resistance to geneticin when the ratio between mutant ribosome and WT
ribosome is close to 1:1. However, when there are 7 copies of genomic ribosome operons present,
the mutant ribosome is not functioning anymore7. One of the key features of our O-ribosome
reporter system is that it only has one copy of WT rRNA operon and another copy of Oribosome. This feature can help us maximize the chance to find more mutations at the drug
binding site. Both WT ribosome and O-ribosome in our system can be used as the target to
examine their interactions with drugs. The O-ribosome controlled fluorescence reporter was
replaced with the O-ribosome controlled chloramphenicol acetyltransferase gene (CAT). CAT
can transfer an acetyl group from acetyl-CoA to chloramphenicol and consequently prevent
chloramphenicol binds to ribosome. The activity of CAT can be titrated by adding a
concentration range of chloramphenicol. Therefore it is a perfect selection marker for selecting
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O-ribosome mutants with different catalytic activity. The scheme of O-ribosome controlled CAT
and its advantages is shown in figure 4-1. We anticipate different results will be observed from
the two types of ribosomes. It would be interesting to compare the result in parallel.

Figure 4-1 The scheme of O-ribosome controlled CAT and its advantages
One of the goals to study drug-resistant rRNA mutations is to learn how the mutations
evolve in nature and anticipate possible new drug-resistant mutation in the future8. Current
approaches to find drug-resistant mutations include structure-guided mutagenesis9, 10 and clinical
isolations of drug-resistant pathogens11, 12. Neither of these methods can comprehensively study
the possible mutations at the drug binding sites. Single point mutation is usually studied by these
methods due to the difficulty to isolate mutations on functionally important part on ribosome 13.
We propose to use directed evolution in which saturation mutagenesis was applied to drug
binding site and mutants are selected towards specific drug resistance. We envision many new
mutations, especially compensatory mutations, with special properties can be found.
As a proof of concept, we chose 3 aminoglycoside antibiotics, kanamycin, neomycin and
gentamicin, as the testing drug to find new mutations at the drug binding site. Kanamycin is a
classic 4, 6-disubstituted deoxystreptamine and neomycin is a classic 4, 5-disubstituted
deoxystreptamine. They are the representative antibiotics of 2-DOS class antibiotic. Kanamycin
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and neomycin also display distinguish signal pattern based on our ribosome inhibition assay by
O-ribosome fluorescence reporter14. Gentamicin shows a unique signal pattern from our
ribosome inhibition assay14, therefore it is also chosen as the testing antibiotic. All of the three
antibiotics bind to the h44 region of 16S rRNA and a variety of drug-resistant mutations had
been found from previous studies. Thus, finding new resistant mutation to the three compounds
should be good examples to prove the advantage of our approach. To comprehensively explore
new mutation at the binding site, we chose 9 sites (1405-1409, 1491, 1494-1496) that are at the
center of the drug binding pocket as the nucleotides to alter. The A1492 and A1493 are left
unchanged due to their essentiality in decoding the mRNA-tRNA recognition during translation15.
Saturation mutagenesis was applied on the 9 sites to maximize the chance of getting new
mutation. The rRNA library was built on both WT ribosome and O-ribosome and the results
were compared to find new insides on aminoglycoside drug binding.
2. Experimental procedures
General. Most of the materials used for work described in this chapter have already been
mentioned in the experimental procedures section of Chapter 2. The concentrated T4 DNA ligase
(2,000,000 units/ml) was purchased from New England Biolabs (Ipswich, MA). The 96-well pin
tool was purchased from V&P Scientific, Inc. (San Diego, CA).
Bacterial strains. All the bacterial strains used for work described in this chapter have
been mentioned in the experimental procedures section of Chapter 2.
Bacterial culture. All of the bacterial culture methods used for work described in this
chapter have been mentioned in the experimental procedures section of Chapter 2.

123

PCR conditions. All of the PCR conditions used for work described in this chapter have
been mentioned in the experimental procedures section of Chapter 2. Gibson assembly reaction
condition is the same as the reported method16.
Enforced replacement by sucrose counterselection. The enforced replacement method
was already described in the experimental procedures section of Chapter 2.
Cell density and fluorescence assays. The methods for measuring cell density and
fluorescence intensity was already described in the experimental procedures section of Chapter 2.
Construction of h44 9-site library on pRRSH2. pRRSH2 was used as the template to
construct the h44 9-site library. The 9-site library plasmid was built by COE-PCR (see
description in chapter 2 experimental procedures). 5 fragments were generated to perform the
COE-PCR. Fragment 1 containing portion of 16S rRNA was amplified using primers pRRSHrRNA1-up and pRRSH2-lib-rRNA1-dn. Fragment 2 containing the p15A origin of replication
and ampicillin resistance marker was amplified using primers pRRSH-AmpR-up and pRRSHp15A-dn. Fragment 3 containing half of 23S rRNA was amplified using primers pRRSHrRNA3-up and pRRSH-rRNA3-dn. Fragment 4 containing another half of 23S rRNA was
amplified using primers pRRSH2-lib-rRNA2-up and pRRSH-rRNA2-dn. Fragment 5 (shown in
figure 4-2) containing the 9-site library was built in 3 steps. First a 132bp fragment containing
the 2 randomized DNA regions at both ends was amplified using degenerate primers 16S9er-lib2-up and 16S9er-lib-2-dn. The primers were designed to exclude the wild type sequence at the
randomized regions. Secondly, 2 fragments containing overlapping ends to the 132bp fragment
were amplified using primer pairs 16S9er-lib-1-up/16S9er-lib-1-dn and 16S9er-lib-3-up/16S9erlib-3-dn. Thirdly, the 132bp fragment was assembled with the 2 fragments by primerless PCR to
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generate fragment 5. These 5 fragments were used to build pRRSH2 with the h44 9-site library
by COE-PCR and the reaction mixture was concentrated using the Zymo Clean and Concentrator
Kit, and introduced into competent E.coli DH10B cells by electroporation. The transformants
were serial diluted to count the colony forming unit (cfu). About 2.55×106 cfu was obtained from
3 transformations (around 10-fold coverage of 2.6 × 105 theoretical diversity). Library quality
was assessed by sequencing of 10 naive clones. Primer information is given in the table 4-1
below. The randomized regions on degenerate primers were colored in bold red.

primer name

sequence (5' -3' )

amplicon
size (bp)

template

pRRSH2-lib-rRNA1-dn

GTCTCCTTTGAGTTCCCGGC (used with pRRSH-rRNA1-up)

1531

pRRSH2

pRRSH2-lib-rRNA2-up

CATCTTCGGGTGATGTTTGAGATTTTTGCTCTTTAAAAATCTGG
(used with pRRSH-rRNA2-dn)

1909

pRRSH2

16S9er-lib-1-up

GCAAAAATCTCAAACATCACCCGAAGATGAG

366

pRRSH2

16S9er-lib-1-dn

ACAAGGTAACCGTAGGGGAACCTG

16S9er-lib-2-up-1491D

CCCTACGGTTACCTTGTTACNNNTTDACCCCAGTCATGAATCAC

16S9er-lib-2-up-1494D

CCCTACGGTTACCTTGTTACNNDTTNACCCCAGTCATGAATCAC

16S9er-lib-2-up-1495B

CCCTACGGTTACCTTGTTACNBNTTNACCCCAGTCATGAATCAC

16S9er-lib-2-up-1496H

CCCTACGGTTACCTTGTTACHNNTTNACCCCAGTCATGAATCAC

16S9er-lib-2-dn-1405H

GGGCCTTGTACACACCGCCCHNNNNACCATGGGAGTGGGTTG

132

pRRSH2

16S9er-lib-2-dn-1406V

GGGCCTTGTACACACCGCCCNVNNNACCATGGGAGTGGGTTG

16S9er-lib-2-dn-1407D

GGGCCTTGTACACACCGCCCNNDNNACCATGGGAGTGGGTTG

16S9er-lib-2-dn-1408B

GGGCCTTGTACACACCGCCCNNNBNACCATGGGAGTGGGTTG

16S9er-lib-2-dn-1409D

GGGCCTTGTACACACCGCCCNNNNDACCATGGGAGTGGGTTG

16S9er-lib-3-up

GGTGTGTACAAGGCCCGGGAAC

262

pRRSH2

16S9er-lib-3-dn

GCCGGGAACTCAAAGGAGACTGCCAG

Table 4-1. Primers for constructing h44 9-site library
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Figure 4-2. The fragment 5 for construction h44 9-site library
Transferring the h44 library into SQ380+pSH6KF. The h44 9-site library E.coli DH10B
transformants were scraped from LB agar plates and the OD600 was quantified by cell density
meter. The library transformants were inoculated into LB medium to grow to OD600=4. Cells
were collected by centrifuge and the plasmids were isolated and purified using the QIAGEN
Plasmid Mini Kit. 1µg of the library plasmid DNA and 1µg of the pRRSH2 was transformed into
competent E.coli SQ380+pSH6KF cells by electroporation. The transformants were serial diluted
to count the cfu. About 1.57×106 cfu was obtained from pRRSH2 transformation (around 6-fold
coverage of 2.6 × 105 theoretical diversity), indicating 1µg of library plasmid DNA should be
enough for transformation to cover the diversity. About 2.1×105 cfu was obtained from 1µg of
library plasmid transformation. This result indicates around 13% of the mutants (calculated by
dividing 2.1×105 cfu with 1.57×106 cfu) can co-exist with WT rRNA operon (prrnC-sacB). All
the h44 9-site library transformants were scraped from LB agar plates and the OD600 was
quantified. 2.6 × 108 cells (1000-fold coverage of 2.6 × 105 theoretical diversity) were used to
select on 5% sucrose LB agar plate for curing out WT rRNA operon (prrnC-sacB). Around 8,500
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colonies were obtained from sucrose counter-selection. They were collected for further selection
and screening by aminoglycoside antibiotics.
Aminoglycoside antibiotics selections on h44 9-site library. The 8,500 colonies were
scraped from LB agar plate and quantified the OD600. Around 1,000 cells were used to select on
12 aminoglycoside antibiotics (the same set of antibiotics used in chapter 2) with killing
concentrations, respectively. The killing concentrations of each aminoglycoside antibiotics used
in this work were shown in table 4-2. Numbers of survivors on each aminoglycoside antibiotic
selection plate were counted and shown in figure 4-2. To further characterize the phenotypes of
these survivors, they were subjected to the second round of cross selection against the 12
aminoglycoside antibiotics. Various numbers of colonies were picked from each aminoglycoside
antibiotic selection plate. Totally 228 survivors were grown up in 3 96-deep-well plates without
the addition of aminoglycoside antibiotics. The survivors were then transferred and selected on
12 aminoglycoside antibiotics agar plates using the 96-well pin tool, respectively. The growth
and fluorescence of each survivor on each of the 12 aminoglycosides was recorded and they
were grouped by their phenotypes. Various mutants from each group were picked and sequence
the mutated part of the 16S rRNA.
Kan Apr Neo Gm Paro G418 Hyg Ami Sis Rib Nea Tob
Concentration
150 150
(µM)
Number of
22 16
survivors

20

20

50

40

90

30

10

60

500

20

22

22

36

52

27

2

19

0

0

0

Table 4-2. Concentration of each antibiotic used in this work. They were chosen from the result
in chapter 2. The ribosome activity should be completely shut down at these concentrations.

Construction and testing of pSH-OCAT. This plasmid, which contains the
chloramphenicol acetyltransferase gene under control of the constitutive promoter BBa_J23016
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and O-SD-KF sequence (see chapter 2 for detail), pMB1 origin of replication, O-16S rRNA
fragment from pSH6-KF and DHFR selection marker was constructed from four fragments by
Gibson assembly. The chloramphenicol acetyltransferase gene fragment was built by sequential
PCR. The chloramphenicol acetyltransferase gene was amplified from pSH6-KF using primers
CG-cat-up-1 and GC-cat-dn. The PCR product was purified and used as the template for the
sequential PCR using primers CG-cat-up-2 and GC-cat-dn. The resulting 929bp PCR product
was used for the Gibson assembly to build pSH-OCAT. The pMB1 origin of replication was
amplified from pUC19 using primers F3-up-tetRassem and pCL-F3-pMB1-dn. The DHFR gene
was amplified from pSH18 using primers CG-DHFR-up and CG-DHFR-dn. The O-16S rRNA
fragment was amplified from pSH6-KF using primers pB15-dn and CG-O16S-dn. The resulting
four fragments were assembled by Gibson assembly. The reaction mixture was concentrated
using the Zymo Clean and Concentrator Kit, and introduced into competent E.coli DH5ɑ cells.
The final construct was verified by restriction mapping and sequencing. Primer information is
given in the table 4-3 below. The plasmid map of pSH-OCAT is shown in figure 4-3.

primer name

sequence (5' -3' )

CG-cat-up-1

CAGCCAGAGAAACAATCGATACATCCCCCGCAAATGGAGAAAAAAATCACTGGATATACC

GC-cat-dn

AGAACCACCACCACCCGCCCCGCCCTGCCACTCATC

CG-cat-up-2

TTTACGGCTAGCTCAGTCCTAGGTATAGTGCTAGCCCAGCCAGAGAAACAATCGATAC

F3-up-tetRassem

GCGGTAATAAGCTTACGGTTATCCAC

pCL-F3-pMB1-dn

AGACCCCGTCTAGATAGAAAAGATCAAAGGATCTTCTTGAG

CG-DHFR-up

GATCTTTTCTATCTAGACGGGGTCTCGAGCTCGATATCAAATTAGGCC

CG-DHFR-dn

GGTACCCGTGGATCCTCTAGAGGATCCAACTGCATTCAGAATAAATAAATCC

pB15-dn

TCTAGAGGATCCACGGGTACC

CG-O16S-dn

CCTAGGACTGAGCTAGCCGTAAACTTGGACTCCTGTTGATAGATCC

Table 4-3. Primers for constructing pSH-OCAT
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amplicon
template
size (bp)
705

pSH6-KF

741

pSH6-KF

738

pUC19

538

pSH18

2150

pSH6-KF

Figure 4-3. Plasmid map of pSH-OCAT
To test whether the O-ribosome activity can represent the WT ribosome activity or not, 4
rRNA single mutations with different fitness cost were chosen to introduce to the WT rRNA
operon (pRRSH2) and O-ribosome (pSH-OCAT), respectively. These four rRNA mutations are
A1408G, U1406A, G1491C and C1496U. The strategy to introduce these mutations onto 16S
rRNA is similar to the strategy described in chapter 3 (see experimental procedure). The
pRRSH2 with each of the four mutations was introduced into SQ380 and replaced the resident
plasmid prrnC-SacB. The resulting E.coli strains and SQ380 (WT rRNA operon) were grown in
LB broth and the growth curve of each strain is measured using micro-plate reader (figure 4-4).
The OD600 was taken every 10 minutes and the strains were set to grow for 24 hours. The pSH-
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OCAT with each of the four mutations and without any mutation was introduced into SQ380.
The resulting E.coli strains were grown in LB broth with the addition of a concentration range of
chloramphenicol. OD600 of each strain in each concentration of chloramphenicol was measured
by micro-plate reader (figure 4-5).

Figure 4-4. Growth curve of E.coli ∆7 strain with different rRNA mutations.

Figure 4-5. Chloramphenicol resistant level of different rRNA mutations on O-16S rNRA .
130

Construction of O-h44 9-site library on pSH-OCAT. pSH-OCAT was used as the
template to build the O-h44 9-site library. The library was built by traditional digestion-ligation.
The 1139bp insert fragment containing the randomized regions, FspI and BsrGI site, was built in
3 steps similar to the construction of h44 9-site library. The 132bp fragment containing the 2
randomized DNA regions at both ends was amplified using degenerate primers 16S9er-lib-2-up
and 16S9er-lib-2-dn. Then the 2 fragments containing overlapping ends to the 132bp fragment
were amplified using primer pairs CG-DHFR-up/16S9er-lib-1-dn and 16S9er-lib-3-up/16S9erlib-3-dn. These three fragments were assembled by primerless PCR to generate the 1139bp insert
fragment. The pSH-OCAT and insert fragment were digested with FspI and BsrGI, gel purified,
ligated and introduced into competent E.coli DH10B cells by electroporation. The transformants
were serial diluted to count the cfu. About 1.678×106 cfu was obtained from 3 transformations
(around 6.4-fold coverage of 2.6 × 105 theoretical diversity). Library quality was assessed by
sequencing of 10 naive clones.
Transferring the O-h44 library into SH471. SH471 was constructed by replacing the
ptRNA67 with ptRNA70 in SQ380. Due to the plasmid origin of replication compatibility,
SH471 displays better transformation efficiency than SQ380. Therefore we chose SH471 as the
host to introduce the O-h44 library plasmid.

The O-h44 9-site library E.coli DH10B

transformants were scraped from LB agar plates and the OD600 was quantified. The library
transformants were inoculated into LB medium to grow to OD600=4. Cells were collected by
centrifuge and the plasmids were isolated and purified using the QIAGEN Plasmid Mini Kit. 1µg
of the O-h44 library plasmid DNA was transformed into competent E.coli SH471 cells by
electroporation. About 2.46×106 cfu was obtained from 2 transformations (around 9.4-fold
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coverage of 2.6 × 105 theoretical diversity). All the transformants were scraped from the LB agar
plates for further selections and the OD600 was quantified.
Ribosome activity selection and aminoglycoside antibiotics selection on O-h44 library.
To select for rRNA mutants that possess different translation activity, the O-h44 library
transformants were grown on 15 concentrations of chloramphenicol LB agar plates. Survival on
each concentration of chloramphenicol represents O-ribosome translation activity. 108 cells of
the O-h44 library transformants were used to select on each concentrations of chloramphenicol
LB agar plate. Numbers of survivors on each chloramphenicol concentration plate were counted
and summarized in table 4-4. 6 colonies from each chloramphenicol concentration plate were
picked to sequence the randomized regions on O-16S rRNA.
Chloramphenicol
(µg/mL)
Number of
survivor

0

10

20

30

40

50

60

70

80

90

100

110

120

130

140

150

6x107

8.3x105

1.3x104

1800

571

231

178

187

256

289

164

138

111

114

88

80

Table 4-4. Numbers of survivors on each chloramphenicol concentration plate.

Kanamycin, neomycin and gentamicin were chosen as the testing compounds for
aminoglycoside antibiotics selections due to their representative structure feature. Killing
concentrations of the three compounds were chosen for selecting mutants that are resistant to
drug binding. 108 cells of naive library were used to select on killing concentrations of the three
antibiotics

respectively

with

20µg/mL

chloramphenicol.

The

addition

of

20µg/mL

chloramphenicol is to select the mutants with partial catalytic activity. 96 survivors from each of
the three antibiotics selection were picked and their randomized regions on O-16S rRNA were
sequenced.
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Totally 155 unique mutants were identified from ribosome activity selection and
aminoglycoside antibiotics selection. The ribosome activities of these mutants were determined
by measuring their resistance level to chloramphenicol with and without aminoglycoside
antibiotics. The 155 mutants and the control E.coli strain (with WT O-16S rRNA) were grown
on 10 concentrations of chloramphenicol LB agar plates with or without killing concentrations of
the 3 antibiotics. The phenotypes of each mutant on each condition were recorded and
summarized.
3. Results and discussion
Aminoglycoside antibiotics resistant mutants from h44 9-site library. The h44 9-site
library was first selected for the mutants that can support the cell growth without WT ribosome
present. The diversity after the selection was estimated to be 76 based on calculation of diversity
lost. This means 99.97% of the library members were not suitable for supporting cell growth.
The survivors were used to do a two-round aminoglycoside antibiotics selection. The first round
is selected on 12 aminoglycoside antibiotics respectively. Each antibiotic was used with a certain
concentration that can inhibit ribosome function. Survivors from the first round selection were
used to select on each of the 12 antibiotics with the same concentration used in the first round
selection. The survivors were then grouped by their phenotypes on the 12 antibiotics. Two
groups were summarized and the phenotypes of the mutants in each group were shown in figure
4-6. Mutants in the same group display variance in fluorescence intensity. Mutants with different
fluorescence patterns were chosen to sequence the randomized regions. The sequencing results
show mutants from the same group have the same mutation on the randomized regions despite
they display different fluorescence signal pattern. Mutants in group I have the same mutation
G1491U. Mutants in group I have the same mutation A1408G. Both mutations had been reported
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previously. This result suggests the two mutations, G1491U and A1408G, can not only confer
broad spectrum of antibiotic resistance, but also retain the ribosome activity to translation the
whole proteome and support the cell growth.

Figure 4-6. The phenotypes of mutants from h44 9-site library group I and group II
Unlike our prediction that new mutations should be found after randomized the whole
drug bind site, only two known mutations were found after extensive selections on
aminoglycoside antibiotics. It suggests there is a balance between drug resistance evolution and
bacterial fitness. Even though the h44 9-site library may contain many drug resistance sequences
at the randomized regions, they cannot go through the selections due to the bacterial fitness lost.
We found that our result correlates with a report from Erik Böttger’s lab. They reconstructed the
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aminoglycoside antibiotics drug resistance evolution in Mycobacterium tuberculosis by
introducing compensatory mutations on drug binding site. They found that A1408G and G1491U
are the only two mutations that can confer decent drug resistance and have less fitness cost 9. The
results from h44 9-site library selection indicate that altering the highly conserved h44 decoding
A-site on WT 16S rRNA has very limited space to find new mutation due to the bacterial fitness
cost.
Ribosome activity selection on O-h44 9-site library. One of the major advantages of
building the h44 9-site library on O-ribosome is the activity of O-ribosome with mutations can
be quantified by measuring the chloramphenicol resistance level. The O-h44 9-site library was
selected for mutants with different ribosome activities by growing the naive library on a set of 15
chloramphenicol concentrations. Large amounts of the library members retain less than 10%
activity (table 4-4). This result again shows the importance of h44 region to ribosome activity.
The sequencing results of mutants from each chloramphenicol concentration selection show
there are 64 unique mutants from 84 sequenced samples. The sequences of these mutants at the
randomized regions display large variance compared to WT sequence. Interestingly, all the 5
nucleotides at randomized region 1 displays strong bias to guanine, and all the 4 nucleotides at
randomized region 2 displays strong bias to cytosine (Figure 4-7). A number of hyperactive
ribosomes which can confer higher chloramphenicol resistance level than the WT ribosome
(survive up to 100µg/mL chloramphenicol) have been sequenced the randomized regions. Strong
bias were observed at 1408 (A to G), 1494 (G to U) and 1495 (T to C or A). It has been
suggested the hyperactive ribosome may lead to increasing rate of miscoding17. Considering the
randomized regions are at the center of the decoding A-site, it would not be surprise many
hyperactive ribosomes can be select out from ribosome activity selection. These results prove our
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assumption that O-ribosome controlling translation of a single gene has much larger space to be
altered than the WT ribosome controlling translation of the whole proteome.

Figure 4-7 Sequence preference of mutants at randomized regions from ribosome activity
selection.

Aminoglycoside antibiotics selection on O-h44 9-site library. To perform aminoglycoside
antibiotics selections, a certain concentration of chloramphenicol needs to be added to retain
partial of ribosome activity while selecting for mutations that disrupt drug binding. 20µg/mL
chloramphenicol was chosen based on the survivor numbers during ribosome activity selection.
The O-h44 9-site library was selected on 20µg/mL with 150µM kanamycin, 20µM neomycin and
20µM gentamicin respectively. 96 survivors from each selection condition were sequenced the
randomized regions. The sequencing results show large sequence variance on the survivors from
all three selection conditions. The mutants from kanamycin selection show strong bias to guanine
at position 1405, 1407, 1408 and 1409, and strong bias to cytosine at position 1491 and 1495 on
the O-16S rRNA (figure 4-8). The mutants from neomycin selection show strong bias to guanine
at position 1405, 1406, 1407, 1409 and 1496, strong bias to uracil on position 1408 and strong
bias to cytosine at position 1491, 1494 and 1495 on the O-16S rRNA (Figure 4-8). The mutants
from gentamicin selection show strong bias to guanine at position 1405, 1406, 1407 and 1495,
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strong bias to uracil on position 1408 and strong bias to cytosine at position 1491 on the O-16S
rRNA (Figure 4-8). In general, guanine is highly favorable at position 1405 and 1407; cytosine is
highly favorable at position 1491.For position 1405, guanine is the WT nucleotide. Therefore the
G1405 might be important for ribosome to retain catalytic activity. For position 1407 and 1491,
changing to guanine and cytosine may contribute to conformational change on h44 region and
consequently disrupt the drug binding. Compensatory mutations were observed on most of the
mutants, suggesting the impact on ribosome activity from single rRNA mutation can be relieved
by the corresponding compensatory mutations.

A.

B.

137

C.
Figure 4-8. Sequence preference of mutants at randomized regions from kanamycin (A),
neomycin (B) and gentamicin (C) selection.

To further characterize the phenotypes of O-h44 library mutants, all the unique mutants
isolated from ribosome activity selection and aminoglycoside antibiotics selections were grown
on a set of 10 chloramphenicol concentrations with or without aminoglycoside antibiotics to
determine their O-ribosome activity in different conditions. Totally 155 mutants plus the WT Oribosome control strain were used to measure their chloramphenicol resistance level with or
without drugs. The results show all the mutants can be divided into 3 groups. Group I is drugresistant mutants. These mutants display same chloramphenicol resistance level with or without
drugs. Group II is drug-sensitive mutants. These mutants show lower chloramphenicol resistance
level in the presence of drugs. Group III is drug-dependent mutants. These mutants show higher
chloramphenicol resistance level in the presence of drugs (figure 4-9). Interestingly, some of the
hyperactive ribosome also display strong drug resistance. However we were not able to find
these mutants from the h44 9-site library. It suggests that despite the hyperactive ribosomes can
confer high drug resistance and produce higher translation activity on a certain gene, they are
less likely to be able to support cell growth alone. This is probably due to the high miscoding
rate of these hyperactive ribosomes cannot satisfy the requirement to translate the whole
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proteome. Nevertheless, they are still possible to show up as small population of mutated
ribosome in nature and cause drug resistance issue.

A.

B.
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C.
Figure 4-9. Ribosome activity of 155 unique mutants with and without kanamyc (A) neomycin
(B) and gentamicin (C). The X axis represents the chloramphenicol concentrations in the absence
of drugs. The Y axis represents the chloramphenicol concentrations in the presence of drugs.
‘*number’ represents the number of mutants site at the same data point.

4. Conclusion
We have developed an O-ribosome controlled reporter system to study the
aminoglycoside antibiotics binding sites on 16S rRNA by directed evolution approach.
Saturation mutagenesis was applied to randomize the h44 region of 16S rRNA on both WT
ribosome (h44 9-site library) and O-ribosome (O-h44 9-site library). The statistic results from
both libraries after activity selection show that O-ribosome has much larger genetic space to be
engineered. Hyperactive ribosomes were found from the O-h44 9-site library but not from the
h44 9-site library. It suggests the hyperactive ribosomes are not able to support cell growth by
itself but may still exist as small population of mutated ribosomes in nature.
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The O-ribosome mutants with partial catalytic activity were used to examine their
interactions to three representative aminoglycoside antibiotics. Mutants isolated from each drug
selection display diverse sequence preference on drug binding site. G1405 position is the most
conserved site among all the mutated sites. Strong guanine bias was observed on position 14051409 and cytosine bias was observed on position 1491, 1494-1496. This observation suggests a
GC rich h44 drug binding site can strongly affect the drug binding in either positive or negative
way. To further characterize the effect of the mutated rRNA sequence to drug binding, we
determine the catalytic activity of all the unique mutants from both ribosome activity selection
and aminoglycoside drug selections with or without addition of drugs. Three types of mutants
were found based on their catalytic activity with and without drugs. Surprisingly, the drugresistant mutants show up as the dominant phenotypes on both kanamycin and neomycin tests. It
suggests the diversity of drug-resistant mutated ribosome is underestimated. However, due to the
bacterial fitness cost or catalytic defect of these mutated ribosomes, they are less likely to show
up in nature as the major ribosome population. Nevertheless, some of them, especially the
hyperactive drug-resistant ribosome, may still exist as minor population and cause concern on
the terrible drug-resistance issue.
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